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The ectopic expression of two brain-enriched microRNAs (miRNAs), miR-9/9* and miR-124 
(miR-9/9*-124), can robustly and efficiently reprogram human skin fibroblasts into neurons. The 
miRNAs act as repressors of non-neuronal genes in fibroblasts for the induction of the neuronal 
program. This process is analogous to neurogenesis in vivo when the expression of miR-9/9* and 
miR-124 represses anti-neurogenic genes such as REST or NRSF (neuron-restrictive silencer 
factor/repressor element-1 silencing transcription factor). Although we have some mechanistic 
insights into how miR-9/9*-124 drives fate conversion by acting as negative regulators of gene 
expression, little remained understood of the role of miRNAs as positive regulators of gene 
expression for the activation of neuronal fate. In this thesis, we present our current understanding 
of how miR-9/9*-124 drives neuronal reprogramming as well as the mechanistic insights into 
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how miR-9/9*-124 can promote expression of neuronal genes. Based on Argonuate (AGO) 
HITS-CLIP, we uncovered that AGO is bound to neuronal transcripts that are progressively 
upregulated during reprogramming. Such observation suggests that contrary to the canonical 
repressive roles of miRNAs, miR-9/9*-124 may be playing a positive role in the expression of 
bound neuronal transcripts. Using PTB family of RNA-binding proteins as an example, we 
delineate a mechanism by which miR-124 can simultaneously repress PTBP1, the non-neuronal 
PTB homolog, while promoting the upregulation of PTBP2, the neuronal PTB homolog, in 
neurons. This process requires the synergism of miRNA targeting as well as a family of neuronal 
ELAVL proteins (nELAVLs). We further showed that this miRNA- and nELAVL-mediated 
upregulation of PTBP2 is neither unique to the conversion process nor PTBP2 transcript alone, 
but also in primary human neurons and is likely a mechanism used to regulate other neuronal 
transcripts. With PTBP2 expression induced in neurons, PTBP2 is involved in the alternative 
splicing of numerous neuronal transcripts. Such transcript includes a subunit of the chromatin 
remodeling complex, DPF1. Although detailed function of DPF1 remains unclear in neurons, 
different PTBP2-mediated DPF1 spliced isoforms are likely involved in the interaction of 









Chapter 1: Introduction 
 
In part from: 
Mechanistic insights into microRNA-induced neuronal reprogramming of human adult 
fibroblasts. 
Ya-Lin Lu & Andrew S. Yoo 












Overcoming epigenetic barriers through direct cellular reprogramming has allowed 
scientists to rapidly acquire cell types of interest for regenerative therapies and disease modeling. 
Direct conversion of mouse fibroblasts into functional neurons have been demonstrated through 
the use of transcription factors (Blanchard et al., 2015; Chanda et al., 2014; Son et al., 2011; 
Vierbuchen et al., 2010). Empirically, however, obtaining mature human neurons from adult 
human fibroblasts with transcription factors have been challenging (Caiazzo et al., 2011). To 
enhance reprogramming efficiency and to promote neuronal maturation, small chemical 
molecules (Ladewig et al., 2012; Liu et al., 2013; Pfisterer et al., 2016; Smith et al., 2016) and 
RNA molecules, miRNAs (Abernathy et al., 2017a; Ambasudhan et al., 2011; Victor et al., 2014; 
Yoo et al., 2011), have been used in conjunction with transcription factors to robustly generate 
functional neurons from human fibroblasts. The mechanism(s) by which miR-9/9* and miR-124 
collectively drive robust neuronal fate conversion remains an ongoing investigation, but by 
examining specific microRNA targets, my thesis work aims to elucidate how miRNAs promote 
the neuronal program during the direct conversion of human fibroblasts to neurons. 
MiR-9/9* and miR-124 (miR-9/9*-124) are efficient reprogramming effectors that, when 
ectopically expressed in human adult fibroblasts (HAFs), induce an extensive reconfiguration of 
the chromatin accessibility landscape leading to the erasure of fibroblast fate and activation of 
the neuronal program (Abernathy et al. 2017). The conversion process by miR-9/9*-124 shares 
similarities to molecular cascades underlying neurogenesis during neural development such as 
the downregulation of REST, a well-established transcription repressor of neuronal genes (Ballas 
et al., 2005; Lee et al., 2018; Schoenherr and Anderson, 1995) and switching of homologous 
chromatin modifiers from non-neuronal to neuronal counterparts including DNMT3B to 
DNMT3A, subunits of BAF/BRM-associated factor (BAF) complexes, and TOP2A to TOP2B 
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(Abernathy et al. 2017; Lee et al. 2018; Lessard et al. 2007; Staahl et al. 2013; Watanabe et al. 
1994; Yoo et al. 2009; Tsutsui et al. 2001). Although the direct repression by brain-enriched 
miRNAs on non-neuronal targets, for instance, REST (Packer et al., 2008; Visvanathan et al., 
2007), ACTL6A (Yoo et al., 2009), and PTBP1 (Makeyev et al., 2007) for the induction of 
neuronal counterparts offer a classic representation of miRNAs acting as negative regulators of 
downstream target genes, how these miRNAs function in the midst of neuronal milieu remains 
unknown.  
 The robustness of miRNA-based neuronal reprogramming allows for the investigation of 
the pathways downstream of miR-9/9*-124 that promote neuronal identity (Abernathy et al. 
2017). In my thesis work, we employed high-throughput sequencing of RNA isolated by 
crosslinking immunoprecipitation (HITS-CLIP) of Argonaute (AGO) during miR-9/9*-124-
mediated neuronal reprogramming of human fibroblasts to map miR-9/9*-124-target interactions 
at the onset of neuronal fate acquisition. Unexpectedly, we identified a suite of neuronal genes 
enriched with AGO binding, in particular, corresponding to the binding sites of miR-124. The 
upregulation of these neuronal genes required miR-124, suggesting that miR-124 not only 
function as a repressor, but also as an effector to promote neuronal gene expression. Although 
the ability of miRNAs as a positive effector of downstream target genes has been implicated 
before (Truesdell et al., 2012; Vasudevan et al., 2007; Vasudevan and Steitz, 2007), little is 
known about the molecular mechanism that governs a miRNA’s activity as an activator in 
neurons.  
Among the genes identified to be targeted and upregulated by miR-124 was PTBP2, a 
neuron-enriched RNA-binding protein (RBP). We elected to further focus on PTBP2 to 
understand the mechanism underlying miR-124 as an activator because the miR-124-PTBP2 axis 
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presented intriguing questions. A non-neuronal homolog PTBP1 (Boutz et al., 2007) and PTBP2 
both contain miR-124 target sites at their 3’UTRs (Makeyev et al., 2007; Y. Xue et al., 2016). 
Why is there selective repression on PTBP1 while PTBP2 escapes the repression by miR-124 in 
neurons? The current view on the initial activation of PTBP2 points to the activity of PTBP1 as a 
repressor of PTBP2 that is relieved upon miR-124 expression at the onset of neuronal 
differentiation (Makeyev et al., 2007). However, the mechanism by which PTBP2 expression 
persists while being targeted by miR-124 remains unknown. In this study, we describe a series of 
experiments to provide evidence for an RNA-binding protein, ELAVL3, induced in neurons, 
directly acting on PTBP2 3’UTR to mediate the mode of miR-124 as an activator. This 
synergism between miR-124 and ELAVL3 drives the neuronal program in human neurons and 
thus the successful conversion of human fibroblasts.  
The miR-124-mediated induction of PTBP2 is essential for neuronal reprogramming as 
knockdown of PTBP2 results in dysregulated spliced isoforms of neuronal transcripts, including 
DPF1. DPF1 is a subunit of the neuron-specific chromatin remodeling BAF complex. Like the 
switching of PTB proteins, non-neuronal PHF10 switches for neuronal DPF1 and/or DPF3 
subunit in neurons (Lessard et al. 2007). We uncovered that PTBP2 mediates the alternative 
splicing of DPF1 in neurons to generate an isoform with shortened PHD. This splicing event is 
likely required to enhance the binding of DPF1 to histone modifications in neurons. In my thesis, 
we propose a model in which the bifunctional activity of miR-124 is determined by the 
concurrent availability of RBPs for the proper splicing of DPF1 and reconfiguration of the BAF 
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Mechanistic insights into microRNA-induced neuronal reprogramming of human adult 
fibroblasts. 
Ya-Lin Lu & Andrew S. Yoo 




The use of transcriptional factors as cell fate regulators are often the primary focus in the 
direct reprogramming of somatic cells into neurons. However, in human adult fibroblasts, 
deriving functionally mature neurons with high efficiency requires additional neurogenic factors 
such as microRNAs (miRNAs) to evoke a neuronal state permissive to transcription factors to 
exert their reprogramming activities. As such, increasing evidence suggests brain-enriched 
miRNAs, miR-9/9* and miR-124, as potent neurogenic molecules through simultaneously 
targeting of anti-neurogenic effectors while allowing additional transcription factors to generate 
specific subtypes of human neurons. In this review, we will focus on methods that utilize 
neuronal miRNAs and provide mechanistic insights by which neuronal miRNAs, in synergism 
with brain-region specific transcription factors, drive the conversion of human fibroblasts into 
clinically relevant subtypes of neurons. Furthermore, we will provide insights into the age 
signature of directly converted neurons and how the converted human neurons can be utilized to 
model late-onset neurodegenerative disorders. 
MiRNAs as potent cell fate regulators 
Traditionally, transcription factors, in particular, pioneer transcription factors, have been 
viewed as regulators and determinants of cell fate. With domains that can interact directly with 
chromatin and/or other modifier proteins, transcription factors have been widely used for cellular 
reprogramming (Iwafuchi-Doi and Zaret, 2016, 2014), including the generation of induced 
pluripotent stem cells (iPSC) from somatic cells (Takahashi and Yamanaka, 2006). Increasing 
studies across different cellular contexts have revealed that miRNAs are also potent cell fate 
regulators as miRNAs not only target large repertoire of genes in genetic networks but also 
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epigenetic regulators necessary for the remodeling of the chromatin (Gruber and Zavolan, 2013; 
Ivey and Srivastava, 2010; Rajman and Schratt, 2017; Yoo et al., 2009). Subsequently, miRNAs 
have been used to generate iPSCs (Anokye-Danso et al., 2011), cardiomyocytes (Jayawardena et 
al., 2012), and neurons (Yoo et al., 2011) from fibroblasts. 
MiR-9/9* and miR-124 are neurogenic molecules 
The acquisition of neuronal fate requires the downregulation of the neuron-restrictive 
silencer factor (NRSF) or repressor element-1 silencing transcription factor (REST) that 
represses neuronal genes in non-neuronal cells, including the neuron-specific miRNAs, miR-9/9* 
and miR-124 (miR-9/9*-124) (Conaco et al., 2006; Deo et al., 2006; Lagos-Quintana et al., 2002; 
Lim et al., 2005). Both miR-9/9* and miR-124 are highly abundant in neuronal tissues (He et al., 
2012; Lagos-Quintana et al., 2002; Lim et al., 2005), and are essential for neuronal 
differentiation (Cheng et al., 2009; Dajas-Bailador et al., 2012; Q. Xue et al., 2016) and the 
maintenance of neuronal identity through the repression of anti-neural genes including cofactors 
of the REST complex, RCOR1 and SCP1 (Packer et al., 2008; Visvanathan et al., 2007). As 
overexpression of miR-9/9* (Leucht et al., 2008; Zhao et al., 2009) and/or miR-124 (Akerblom 
et al., 2012; Cheng et al., 2009; Krichevsky et al., 2006) in stem cells or neural progenitors 
resulted in the precocious acquisition of neuronal fate, demonstrating the function of miRNAs in 
the activation of neuronal program (Lim et al., 2005). Subsequently, knockdown of REST can 
directly convert adult somatic cells into neurons in part due to the induction of neuron-specific 
miRNAs, miR-9/9* and miR-124 (Drouin-Ouellet et al., 2017). Therefore ectopic expression of 
miR-9/9*-124 was also shown to drive the direct conversion of primary human dermal 
fibroblasts into functional neurons (Yoo et al., 2011). Interestingly, miR-124 alone has been used 
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to in neuronal reprogramming with the help of transcriptional factors (Ambasudhan et al., 2011; 
Jiang et al., 2015). Here, we review current understanding of the properties of miR-9/9* and 
miR-124 in both developmental and cellular reprogramming contexts highlighting their 
synergistic roles in coordinating the molecular switching of several critical non-neuronal to 
neuronal components during mammalian neurogenesis. We will mainly focus on the molecular 
switches critical in epigenetic regulation such as chromatin remodeling and DNA methylation, 
and transcriptome dynamics such as alternative splicing underlying the adoption of the neuronal 
identity. Our discussion will also include molecular pathways that occur during in vivo 
neurogenesis and are also recapitulated in the miRNA-directed reprogramming of human 
fibroblasts into neurons for the successful overcoming of cell fate barriers. 
MiRNAs orchestrate the composition of BAF chromatin remodeling 
complexes 
Spatial and temporal reciprocity of homologous gene or isoform expression during 
neurogenesis is a recurring theme. Previous studies have indicated that the neurogenic and 
reprogramming activity of miR-9/9* and miR-124 may be in part through the direct targeting of 
subunits of the ATP-dependent BRG/BRM associated factor (BAF) chromatin remodeling 
complexes (Staahl et al., 2013; Staahl and Crabtree, 2013; Yoo et al., 2009). Mammalian BAF 
complexes are large multi-subunit complexes combinatorically assembled in a cell type-
dependent manner. The combinatorial assembly of different homologs and splice variants of 
BAF subunit families confers functional specificity as each subunit contains functional domains 
that recognized DNA and/or modified histones (Wu et al., 2009; Zheng et al., 2012). For 
example, embryonic stem cell (ESC) BAF (esBAF) is characterized by BAF53a and a 
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homodimer of BAF155, as opposed to a heterodimer of BAF155 and BAF170 in differentiated 
cells (Ho et al., 2009b; Weidong Wang et al., 1996; W Wang et al., 1996). The esBAF complex 
is involved in maintaining pluripotency by establishing an ESC-specific chromatin state 
permissive for transcription factors and signaling molecules to access ESC-associated genes (Ho 
et al., 2009a; Kidder et al., 2009). Although BAF complexes are traditionally known to 
antagonize the function of polycomb repressive complexes (PRC) to promote chromatin 
accessibility for gene activation (Ho et al., 2011; Kennison, 1995), studies have also suggested 
that BAF complexes can synergize with PRC for gene regulation (Ho et al., 2011).  
The BAF complex is crucial for mammalian nervous system as mutations to BAF subunits 
have been implicated in neurological disorders such as Coffin-Sirius syndrome due to mutation 
in BRG1 (Ronan et al., 2013; Tsurusaki et al., 2012) and SS18L1/CREST in amyotrophic lateral 
sclerosis (Chesi et al., 2013). During neural development, several BAF complex subunit switches 
to form the neuron-specific BAF (nBAF) complex (Staahl and Crabtree, 2013). The assembly of 
the nBAF complex requires the switching of progenitor subunits (BAF53a, BAF45a and SS18) 
to neuronal subunits (BAF53b, BAF45b or BAF45c and SS18L1/CREST) between the 
proliferating ventricular zone and the post-mitotic zone (Lessard et al., 2007; Olave, 2002; Staahl 
et al., 2013; Wu et al., 2007; Yoo et al., 2009). These molecular switches also occur during 
miRNA-mediated direct conversion of human fibroblasts into neurons (Staahl et al., 2013), in 
which the reciprocal switching of BAF53a to BAF53b is directly orchestrated by miR-9/9* and 
miR-124 (Staahl et al., 2013; Yoo et al., 2009) (Figure 1). The assembly of the nBAF complex is 
essential for proper neuronal function in learning and memory as loss of function of either 
BAF53b or SS18L1/CREST dramatically reduced dendritic outgrowth and morphology (Aizawa 
et al., 2004; Staahl et al., 2013; Vogel-Ciernia et al., 2013; Wu et al., 2007). The function of 
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chromatin remodeling by BAF complex was also found to be critical for neuronal 
reprogramming as loss of BRG1 during miRNA-mediated reprogramming abolished the 
chromatin landscape permissive to the activation of the neuronal program (Abernathy et al., 
2017a).  
Switching of chromatin modifiers are crucial for cell fate conversion 
The switching of other homologous epigenetic regulators also occur during neurogenesis 
and neuronal reprogramming, though may not be direct targets of miR-9/9*-124. These include 
the switching of DNA topoisomerase II (TOP2) that functions to decatenate and catenate 
chromatin, from non-neuronal TOP2A to neuronal TOP2B (Thakurela et al., 2013; Tiwari et al., 
2012; Tsutsui et al., 2001a; Watanabe et al., 1994). TOP2A is expressed in mitotic cells and 
interacts with BAF complexes to modulate chromatin accessibility (Dykhuizen et al., 2013; 
Miller et al., 2017; Ken Tsutsui et al., 2001; Wijdeven et al., 2015). On the other hand, TOP2B is 
required for neuronal differentiation in vitro and in vivo (Tiwari et al., 2012; Ken Tsutsui et al., 
2001; Yang, 2000). Consistent with neuronal differentiation, miR-9/9*-124 instruct the similar 
switch of TOP2 homologs during neuronal reprogramming of human adult fibroblasts by 
inducing a rapid reduction of TOP2A in fibroblasts for the selective expression TOP2B in 
converted neurons (Abernathy et al., 2017a) (Figure 1). 
Similarly, the reconfiguration of the epigenetic landscape during neuronal reprogramming 
also involves changes in DNA methylation patterns (Abernathy et al., 2017a). Regarding the 






124 in fibroblasts recapitulated the molecular switching of de novo methyltransferases, 
DNMT3B to DNMT3A, similarly to neural differentiation in vivo (Abernathy et al., 2017a; Feng 
et al., 2005; Watanabe et al., 2006) (Figure 1). DNMT3A has been implicated in various aspects 
of neuronal development, including synaptic plasticity (Colquitt et al., 2014; Feng et al., 2010), 
but it remains unclear how DNMT3A modulates gene expression in the nervous system. 
Although DNA methylation is viewed as a repressive mark, methylation marks deposited by 
DNMT3A have also been associated with enhanced gene expression through antagonizing PRC2 
activity (Wu et al., 2010). The dramatic change in DNA methylation profile in miRNA-induced 
neurons also involves the induction of a family of demethylase, ten-eleven translocation (TET) 
family proteins (TET1/2/3) (Abernathy et al., 2017a), implicated in neuronal development (Hahn 
et al., 2013; Zhang et al., 2013). It should be noted, however, what additional molecules interact 
with DNMT3A and TET proteins during neuronal reprogramming to influence DNA methylation 
at specific loci remains largely unknown. 
Although the mechanisms underlying the switching of epigenetic effectors remain to be 
precisely defined, it is clear that miR-9/9*-124 promote neuronal identity during the direct 
reprogramming of human fibroblasts through establishing an epigenetic state permissive for the 
downstream acquisition of neuronal fate. The reciprocal temporal and spatial switching of 
chromatin modifiers observed both during neurogenesis and neuronal reprogramming highlight 
the complex and dynamic epigenetic regulations required to overcome cell fate barriers.  




In addition to epigenetic regulators, post-transcriptional regulation of gene expression 
appears to be integral for neuronal reprogramming. The expression of PTB (polypyrimidine 
tract-binding) proteins, PTBP1 and PTBP2, are mutually exclusive and exhibit reciprocal 
switching during neural fate acquisition (Boutz et al., 2007). PTB proteins are RNA-binding 
proteins that bind to U-rich tracts primarily in introns for the post-transcriptional regulation of 
mRNAs, including alternative splicing (Keppetipola et al., 2012; Wagner and Garcia-Blanco, 
2001). PTBP1 is expressed in non-neuronal cells and neural progenitors whereas the expression 
of its neuronal homolog, PTBP2 (nPTB), a splicing target of PTBP1, is primarily restricted to 
post-mitotic neurons in the nervous system (Boutz et al., 2007; Makeyev et al., 2007). PTBP1 
represses PTBP2 expression by introducing a premature stop through the skipping of PTBP2 
exon (Boutz et al., 2007). During development, the expression of miR-124 at the onset of 
neurogenesis mediates the switching of PTB proteins by targeting the 3’UTR of PTBP1, thereby 
alleviating PTBP1-mediated repression of PTBP2 in neurons (Makeyev et al., 2007). Although 
PTB proteins exhibit functional redundancy (Spellman et al., 2007), PTBP2 in neurons are 
essential for the proper splicing of various transcripts involved in neuronal function (Boutz et al., 
2007; Li et al., 2014; Licatalosi et al., 2012; Zheng et al., 2012). Interestingly, ablating PTBP1 
function in several cell types, including mouse embryonic fibroblasts, though insufficient in 
human fibroblasts, led to the direct conversion into neurons (Xue et al., 2013; Y. Xue et al., 
2016), suggesting the significance of PTBP2 for the induction of neuronal fate. In addition to the 
activation of PTBP2 upon neural fate acquisition, PTBP2 level attenuates later in development 
for neuronal maturation (Li et al., 2014; Y. Xue et al., 2016). The attenuation of PTBP2 can be 
recapitulated with sequential knockdown of both PTB proteins resulting in the reprogramming of 
human adult fibroblasts into neurons (Y. Xue et al., 2016). The proposed mechanism is that 
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PTBP2 reduction initiates a regulatory loop that activates downstream BRN2 for miR-9 
expression, which dampens PTBP2 activity through 3’UTR targeting (Y. Xue et al., 2016). 
Together, PTBP2 level is dynamically regulated throughout neuronal differentiation and is 
essential as PTBP2 knockout results in neuronal death (Li et al., 2014; Y. Xue et al., 2016).  
The use of miRNA-induced neuronal ground state for subtype-
specific neuronal reprogramming 
As neurological disorders affect distinct neuronal subtypes, the generation of neuronal 
subtypes has been of interest not only for dissecting the underlying mechanisms behind subtype-
specific neuronal conversion, but also for the implication of the reprogrammed neurons in 
disease modeling. MiR-9/9*-124 have been shown to induce a “default” neuronal state 
characterized by enhanced accessibility of chromatin regions encompassing neuronal genes 
(Figure 2). These regions include genes specifically expressed in distinct neuronal subtypes, yet 
remain inactivated, thereby providing the chromatin environment that is open and permissive for 
subtype-defining inputs of transcription factors (Abernathy et al., 2017a). Furthermore, unlike 
iPSC-based reprogramming methods, direct neuronal conversion bypasses an embryonic 
intermediate (Lapasset et al., 2011; Miller et al., 2013), thereby retaining the age signatures of 
starting fibroblasts including the epigenetic clock (Horvath, 2013), age-associated changes in 
transcriptome and microRNAs, reactive oxygen species (ROS) levels, DNA damage and 
telomere lengths (Huh et al., 2016; Mertens et al., 2015; Tang et al., 2017). As direct neuronal 
conversion can faithfully recapitulate age-associated phenotypes, directly reprogrammed neurons 
hold promise in the modeling of adult-onset neurodegenerative diseases and necessitates the 
control of subtype-specificity during neuronal reprogramming.  
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The use of synergism between miRNAs and subtype-defining transcription factors to 
obtain subtype-specific neurons has been successful in generating cortical neurons (Yoo et al., 
2011), striatal medium spiny neurons (Victor et al., 2014), and spinal cord motor neurons 
(Abernathy et al., 2017a) (Figure 2). For instance, heterogeneous population of excitatory and 
inhibitory neurons belonging to the cortex can be obtained with the use of miR-9/9*-124 in 
combination with NEUROD2, ASCL1, and MYT1L (DAM) cocktail from adult fibroblasts (Yoo 
et al., 2011). However, it remains to be tested whether layer-enriched transcription factors would 
be able to further guide the cortical lineage to neurons with layer-specific identities. Since 
previous studies demonstrated the plasticity of cortical neurons being able to transition between 
cortical layer fates (De la Rossa et al., 2013; Rouaux and Arlotta, 2013, 2010), it raises the 
potential that a similar approach may be taken in a cellular reprogramming context.   
An enriched population of striatal medium spiny neurons (MSN), the neuronal subtype 
primarily degenerated in Huntington’s disease (HD), can be derived using miR-9/9*-124 in 
conjunction with CTIP2, DLX1/2, and MYT1L (CDM) factors (Victor et al., 2014). More than 
70% of cells express DARPP32, a marker of MSNs, and when injected into the stratum of mouse 
pups, the converted MSNs incorporate and project to the substantia nigra and globus pallidus in 
vivo with electrophysiological properties similar to neighboring endogenous mouse MSNs 
(Victor et al., 2014). Interestingly, applying the MSN-specific neuronal conversion approach in 
fibroblast samples from symptomatic patients has proven to be successful in generating patient-
specific MSNs manifesting hallmark HD pathology, including HTT aggregation, spontaneous 
neuronal death, and increased DNA damage (Victor et al., 2018). Importantly, the manifestation 
of HD-associated phenotypes was dependent on the specificity of the type of neurons generated 
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and the age status in converted neurons, further highlighting the importance of age and subtype-
specificity in modeling adult-onset diseases (Victor et al., 2018). 
Spinal cord motor neurons are most susceptible to degeneration in amyotrophic lateral 
sclerosis (ALS) and spinal muscular atrophy (SMA) diseases, and devising a conversion protocol 
could be instrumental to the study and modeling of motor neuron (MN) diseases. Using a 
combination of NEUROG1, SOX11, ISL1, and LHX3 (NSIL), MNs can be generated from 
fibroblasts of ALS patients in which the patient-derived MNs manifest various ALS pathologies, 
including FUS protein mislocalization and neuronal degeneration (Liu et al., 2016). 
Alternatively, miRNAs in conjunction with two transcription factors, ISL1 and LHX3, have been 
shown to generate functional mature MNs that display transcriptional signatures similar to in 
vivo mouse spinal MNs (Abernathy et al., 2017a). Despite the robustness in generating a highly 
enriched population of spinal cord MNs, it remains to be demonstrated whether the MNs derived 
through the miRNA-induced neuronal state can be used to model ALS or SMA. 
The use of transcription factors only, ASCL1, NURR1, and LMX1A, to directly convert 
fibroblasts of healthy and Parkinson’s disease (PD) patients into dopaminergic cells is possible 
but with limited efficiency in human cells (Caiazzo et al., 2011). Interestingly, reprogramming 
efficiency improved with the addition of neuronal miRNA, miR-124, and shRNA against p53, to 
the transcription factor cocktail using adult fibroblasts (Jiang et al., 2015). One of the proposed 
mechanisms behind this enhancement is due to the activation of TET proteins, in particular 
TET1, during reprogramming, as knockdown of TET1 results in increased cell death while 
overexpression enhances the overall number of TUBB3 and TH positive cells (Jiang et al., 
2015). The induction of TET family members has also been observed in miR-9/9*-124-mediated 
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Figure 2. Synergism between microRNAs and transcription factors for subtype-specific neuronal reprogramming of human 
adult fibroblasts. MiR-9/9*-124 mediate the erasure of fibroblast fate through remodeling of a fibroblast-specific chromatin 
landscape and transcriptome profile and promote a neuronal chromatin landscape and transcriptome. MiRNA alone gener-
ates a default neuronal state characterized by the reconfiguration of the chromatin state permissive to the subtype-defining 
inputs of transcription factors. With distinct combinations of transcription factors, the miRNA-based conversion have been 
successfully employed to generate cortical neurons (Yoo et al., 2011), striatal medium spiny neurons (Victor et al., 2014) and 




The generation of additional neuronal subtypes, including serotonergic neurons for the study of 
neuropsychiatric disorders such as schizophrenia (Vadodaria et al., 2016; Xu et al., 2016) and 
sensory neurons for the study of pain sensation (Blanchard et al., 2015; Wainger et al., 2015) 
have been demonstrated using the transcription factor approach. It remains to be tested whether 
miR-9/9*-124 could be combined with similar transcription factors to enhance overall 
conversion efficiency in human cells. 
Summary 
MiR-9/9*-124-mediated direct conversion of human adult fibroblasts into functional neurons 
reconfigures and establishes a pan-neuronal epigenetic landscape permissive on which brain 
region-enriched transcription factors can act and generate specific neuronal subtype. MiR-9/9*-
124 are potent neurogenic molecules as they mediate numerous genetic switches that occur 
during neurogenesis, in which many include epigenetic players and pro-neurogenic effectors that 
are important to overcome cell fate barriers and activate neuronal fate programs. As miRNAs 
regulate expression of multiple genes, the pro-neural environment established by the miRNAs 
allow for the use of this paradigm for the study of neural fate acquisition. To better understand 
and address the role of brain-enriched miRNAs, examining miRNA-mRNA network would 
provide invaluable insights to the acquisition of neuronal fate. Though much remains to be 
uncovered, with the maintenance of age of starting fibroblasts preserved after cellular 
conversion, modeling age-dependent neurodegenerative diseases through direct reprogramming 
allows for the faithful recapitulation of age-associated pathogenesis for mechanistic studies of 







Chapter 3: Synergism between  
microRNA-124 and ELAVL3 drives 
neuronal gene upregulation in  
human neurons 
 
In part from: 
MiR-124 synergism with ELAVL3 enhances target gene expression to promote neuronal 
maturity. 







Neuron-enriched microRNAs (miRNAs), miR-9/9* and miR-124 (miR-9/9*-124), direct 
cell fate switching of human fibroblasts to neurons when ectopically expressed by repressing 
anti-neurogenic genes. How these miRNAs function after the onset of the transcriptome switch 
to a neuronal fate remains unclear. Here, we identified direct targets of miRNAs by Argonaute 
(AGO) HITS-CLIP as reprogramming cells activate the neuronal program and reveal the role of 
miR-124 that directly promotes the expression of its target genes associated with neuronal 
development and function. The mode of miR-124 as a positive regulator is determined by a 
neuron-enriched RNA-binding protein, ELAVL3, that interacts with AGO and binds target 
transcripts, whereas the non-neuronal ELAVL1 counterpart fails to elevate the miRNA-target 
gene expression. Although existing literature indicate that miRNA-ELAVL1 interaction can 
result in either target gene upregulation or downregulation in a context-dependent manner, we 
specifically identified neuronal ELAVL3 as the driver for miRNA target gene upregulation in 
neurons. In primary human neurons, repressing miR-124 and ELAVL3 led to the downregulation 
of genes involved in neuronal function and process outgrowth, and cellular phenotypes of 
reduced inward currents and neurite outgrowth. Results from our study support the role of miR-
124 promoting neuronal function through positive regulation of its target genes.  
AGO binds both downregulated and upregulated genes during miR-
9/9*-124-mediated direct neuronal reprogramming of human 
fibroblasts 
Previous studies showed that the ectopic expression of miR-9/9*-124 in human adult 
fibroblasts (HAFs) induces a neuronal state characterized by the appearance of neuronal markers 
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(such as MAP2, TUBB3, NCAM, and SNAP25) (Figure 1A) and electrical excitability 
(Abernathy et al. 2017). To identify target genes of miR-9/9*-124 as reprogramming cells 
transition to neuronal identity, we carried out AGO HITS-CLIP after two weeks into 
reprogramming, a time point when neuronal genes are activated (Abernathy et al. 2017), to 
identify transcripts bound with AGO loaded with miR-9/9* or miR-124 over the non-specific 
miRNA (miR-NS) control (Log2FC ≥ 1; adj.P-value < 0.05). We compared these hits to the list 
of differentially expressed genes (DEGs) (by RNA-seq analysis; -1 ≤ Log2FC ≥ 1; adj.P-value < 
0.05) at day 20 of miRNA-induced neurons (miNs) (Abernathy et al. 2017). As expected, we 
found target transcripts that were downregulated consistent with the repressive mode of miRNAs 
(Figure 1B, 113 genes labeled as green dots) including some known targets, SHROOM3 and 
PHF19 (Lu et al., 2018; Neo et al., 2014; Zhou et al., 2014). Interestingly, we also discovered 
453 unique gene transcripts with enriched AGO binding, which were upregulated in day 20 miNs 
(Figure 1B, red dots). By gene ontology (GO) analysis, these upregulated genes with enriched 
AGO loading in response to miR-9/9*-124 were associated with various neuronal processes such 
as synaptic transmission and regulation of membrane potential (red), in contrast to non-neuronal, 
downregulated target genes (green) (Figure 1C). Moreover, when examined against the time-
course transcriptome analysis during neuronal reprogramming (Abernathy et al. 2017), the 
expression of the identified neuronal target genes showed continuous upregulation during later 
time point of neuronal conversion (Figure 1D). For example, neuronal transcripts such as MAP2, 
PTBP2, and SLC4A8 that were highly expressed in day 20 miNs harbored AGO binding sites at 
the 3’UTR (Figure 1E). To determine the fraction of upregulated neuronal genes that are likely 
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Figure 1. Enrichment of AGO binding on transcripts of neuronal genes upregulated during miR-9/9*-124-mediated neuronal conversion
(A) Examples of miR-9/9*-124-mediated direct reprogramming of human adult dermal fibroblasts (HAFs) into neurons (miNs). Photographs show immunostaining of the 
ILEUREODVWPDUNHU6$DQGQHXURQDOPDUNHUV0$378%%1&$0DQG61$36FDOHEDU ȝP
(B) A volcano plot of differentially expressed genes at day 20 miNs and enrichment of AGO binding in response to miR-9/9*-124 expression identified by AGO HITS-CLIP 
analysis. Red dots, day 20 mRNA expression Log2FC 1; adj.P-value < 0.05, AGO binding Log2FC 1, adj.P-value < 0.05. Green dots, day 20 mRNA expression Log2FC 
 -1; adj.P-value < 0.05, AGO binding Log2FC  1, adj.P-value < 0.05.  
(C) Top biological GO terms of upregulated (red) and downregulated (green) DEGs in day 20 miNs differentially bound by AGO. 
(D) Time course heatmap of select upregulated DEGs enriched for AGO binding with miR-9/9*-124 expression.  
(E) Track views of AGO CLIP-seq tracks (top) and RNA-seq tracks (bottom) for gene examples showing the enrichment of AGO binding miR-9/9*-124 expression (over 
control miR-NS) and increased transcript levels at 3’UTRs.
(F) Of the 301 unique upregulated DEGs identified in (A), 207 are predicted to harbor miR-9/9* and/or miR-124 sites at the AGO-enriched regions through RNAhybrid 
prediction. The graph indicates top biological GO terms associated with the 328 upregulated DEGs containing miR-9/9* and/or miR-124 target sites.
(G) Breakdown of the 328 upregulated DEGs in (F) based on common or specific targets of miR-9/9* and/or miR-124.   
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predicted the duplex formation by either miR-9/9* and/or miR-124 through RNAhybrid (a 
maximum free energy threshold of -20 kcal/mol) (Rehmsmeier, 2004). Of the 453 upregulated 
DEGs in miNs bound by AGO (Figure 1B), 328 (~72%) gene transcripts are predicted to contain 
miR-9/9* and/or miR-124 binding sites (Figure 1F). These transcripts harboring miR-9/9*-124 
sites are also associated with the similar set of neuronal GO terms in Figure 1C as they include a 
selection of genes important for neuronal function (Figures 1F). Of these upregulated miR-9/9*-
124 target genes, more than 94% of the total genes (308 of 328 genes) contain miR-124 target 
sequence alone (45%) or with miR-9/9* sites, while less than 6% of the genes (20 genes) contain 
miR-9/9* target sites only (Figure 1G). These results collectively demonstrate that the AGO-
loaded transcripts differentially (up or down) respond to miR-9/9*-124 during neuronal 
conversion. 
MiR-124 target genes are upregulated during neuronal conversion  
As a large fraction of the upregulated genes contained miR-124 target sequences (Figure 
1G), we further tested if the upregulated genes were bona fide targets of miR-124 by knocking 
down miR-124 expression through the use of a tough decoy (TuD) to inhibit miRNA activity 
(Bak et al., 2013; Haraguchi et al., 2009). The effect of the lentivirus-based TuD for miR-124 
(TuD-miR-124) was monitored after transduction by following the concurrent expression of 
TurboRFP reporter built in the lentiviral vector and measuring the mature miR-124 level. TuD-
miR-124 yielded more than 60% reduction of miR-124 expression in comparison to the control, 
non-specific miRNA tough decoy (TuD-miR-NS) (Figure S1A-S1B). We then performed RNA-
seq analysis on day 20 miNs treated with either TuD-miR-NS or TuD-miR-124 to see whether 
any of the miR-124 target would fail to be upregulated with TuD-miR-124 treatment (Figure 2A, 
S1C). When compared with upregulated DEGs in day 20 miNs that were also enriched for AGO 
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binding (Figure 1), we identified 192 genes (Log2FC ≤ 0.5; adj.P-value < 0.01) that failed to be 
upregulated upon miR-124 reduction (Figure 2A, Table S1). With GO analysis, these identified 
genes were associated with neuronal terms involved in various synaptic processes (Figure 2B).  
To further analyze miR-124-target interactions, we looked into the potential duplex 
formations between miR-124 and the identified AGO HITS-CLIP peak regions using 
RNAhybrid (a maximum free energy threshold of -20 kcal/mol) (Rehmsmeier, 2004). Of the 
upregulated transcripts that harbor AGO-enriched peaks, we identified a spectrum of miR-124 
and target mRNA duplex configurations ranging from the canonical 2-8 seed base pairing to non-
canonical base pairing starting at position 3 and 4 (Figures 2C, S1D, and S2). These examples 
include MAP2 3'UTR, in which miR-124 base pairing is predicted to start at position 3, while 
miR-124 target sequences on PTBP2 3’UTR at the two peaks are predicted to start at position 1 
and position 2, respectively (Figure 2C). Interestingly, across the predicted miR-124:target 
duplex configurations, we observed consistent auxiliary 2-3 base pairing at the 3’ end of miR-
124 (Figure S1D). 
 Our results so far indicate that miR-124 can target and promote the expression of select 
neuronal genes when cells acquire the neuronal fate during neuronal conversion. We wondered if 
the active mode of miR-124 would be specific to neuronal cell types. We cloned the 3’UTRs of 
several identified, upregulated targets (MAP2, PTBP2, BCL7A, KALRN, SEMA6A, RCAN2) into 
a luciferase reporter construct and transfected into a non-neuronal cell type, HEK293T (a human 
embryonic kidney cell line), with a miR-9/9*-124 expression construct. After 48 hours post-
transfection, we found that unlike reprogrammed neurons, miR-9/9*-124 instead, repressed the 
luciferase signal in HEK293T cells in comparison to the control miR-NS, while the non-target 





















GUU   AC       CGUGCCUUA
A        G     AUA                        APTBP2 5’
miR-124-3p 3’
UAA   UG       GCACGGAAU
AACCG       G     GC
-23.4 kcal/mol
5’ 3’
GGUG          CA    GU         GUGCCUU
A           GGAC    AA     UUAU                 UPTBP2 5’
miR-124-3p 3’
CCGU          GU    CG         CACGGAA






GCAU     UUACC            UGUGCCU
U          UU            UUUCA                  GMAP2 5’
miR-124-3p 3’
CGUA     AGUGG            GCACGGA





















Figure 2. Identification of miR-124 target genes that fail to be upregulated upon the inhibition of miR-124 during miRNA-mediated neuronal conversion  
(A) Left, miR-124 activity is reduced through the use of tough decoy (TuD). By overlapping with upregulated DEGs bound by AGO (Figure 1), 192 genes were identified as genes that fail to 
be increased upon the reduction of miR-124. Right, a heatmap of z-scores of the 192 genes from RNA-seq comparing miNs between TuD-miR-NS and TuD-miR-124 treatments.  
(B) Top biological GO terms associated with the 192 genes identified in (A). 
(C) Predicted binding of miR-124 to the 3’UTR sequences of neuronal target genes, for example, MAP2 and PTBP2, according to RNAhybrid prediction at the highlighted AGO HITS-CLIP 
peaks. 
(D) Luciferase assays in HEK293T cells of upregulated neuronal target genes of miR-124 selected from A). In the non-neuronal context of HEK293T cells, 3’UTRs from the neuronal genes 
are targeted and repressed, instead, by miR-9/9*-124. Luminescence measured after 48 hrs of transfection and normalized to miR-NS control of each condition. Data are represented by 
mean ± SEM from three independent experiments (from left, ** P = 0.0094, P = 0.0011; *** P < 0.001; * P = 0.048, P = 0.012; *** P < 0.001).
(E) A diagram of the observed phenomenon in which miR-9/9*-124 can promote neuronal identity by simultaneously targeting both non-neuronal genes for repression while promoting the 
expression of neuronal genes during neuronal conversion.
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determinants available in neuronal cells may be in play to govern the activity of miR-124 as a 
positive regulator while simultaneously functioning to repress non-neuronal targets (Figure 2E).  
PTBP1 and PTBP2 3’UTR as targets of miR-124 
To further dissect the mechanism underlying the dual modes of miR-124 on its targets, 
we elected to focus on PTBP2 from the list of our identified neuronal targets because i) PTBP2 
and its non-neuronal homolog, PTBP1, both contain miR-124 sites in their 3’UTRs (Figure 3A), 
and ii) both PTBP1 and PTBP2 3’UTRs are targeted and repressed by miR-124 in HEK293T 
cells (Figure 3A), and iii) contrastingly, as observed in the human brain, qPCR analysis showed 
that the neuronal conversion established the mutually exclusive expression between PTBP1 and 
PTBP2 (Figure 3B). Therefore, the PTB homologs represent an ideal example to investigate how 
two closely related targets respond differently to miR-124.  
The 3’UTRs of human PTBP1 and PTBP2 contain two predicted target sites for miR-124 
(yellow bar) and one site for miR-9 (blue bar) (Figure 3A). Luciferase reporter assays in the non-
neuronal HEK293T cells showed that miR-9/9*-124 or miR-124 alone (but not miR-9/9* alone) 
repressed both PTBP1 and PTBP2 through their 3’UTRs indicating that miR-124 is the primary 
miRNA targeting both PTB 3’UTRs (Figure 3A). Mutating the two miR-124 sites in PTBP2 
3’UTR (s1 and s2) rendered the 3’UTR insensitive to miR-124 (Figure S3A). While our results 
pointing to the ability of miR-124 to target and repress 3’UTRs of both PTBP1 and PTBP2 in 
cell lines were consistent with previous findings (Makeyev et al., 2007; Xue et al., 2016), it 
remains unknown how miRNA-mediated neuronal conversion of HAFs establishes the mutually 
exclusive expression of PTBP1 and PTBP2 as seen in the human brain (Figure 3B) and in in vivo 
neurons (Boutz et al., 2007).  
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Because PTBP1 and PTBP2 are regulated differentially in miNs, we asked whether the 
repressive activity of miR-124 on PTBP2 3’UTR could be reversed with a prolonged neurogenic 
input by miR-9/9*-124 in HEK293T cells. We expressed a destabilized EGFP reporter 
containing PTBP1 3’UTR, PTBP2 3’UTR, or control 3’UTR (CTL) that lacks a 3’UTR in 
HEK293T cells with the miR-9/9*-124 expression construct (Figure S3B). Analogous to PTBP2 
upregulation during neuronal reprogramming of HAFs, we observed the selective repression of 
EGFP with PTBP1 3’UTR but not PTBP2 3’UTR (Figures S3B-C). These results suggest that 
with the prolonged neurogenic input, PTBP2 3’UTR responds to miR-124 differentially from 
when measured after 48 hours with miRNA expression in HEK293T cells (Figures 2A and 3A).  
MiR-124 accentuates PTBP2 expression beyond the induction 
mediated by the downregulation of PTBP1 
Previous studies have shown that during development, PTBP1 destabilizes PTBP2 
transcript in non-neuronal cells by alternative splicing, and at the onset of neurogenesis, miR-124 
directly represses PTBP1 resulting in PTBP2 induction (Boutz et al., 2007; Makeyev et al., 
2007). Upon miR-9/9*-124 expression in HAFs, we observed the concomitant downregulation 
and upregulation of endogenous PTBP1 and PTBP2, respectively (Figure 3B). As expected, the 
initial PTBP2 upregulation was abrogated when PTBP1 cDNA was overexpressed (Figure 3C), 
supporting the role of PTBP1 reduction as the initiation step of PTBP2 expression. We then 
sought to stratify the contribution of PTBP1 repression alone versus the input of miRNAs to the 
overall PTBP2 level. When PTBP2 protein levels were compared between PTBP1 knockdown 
with a short hairpin RNA (shRNA) and miR-9/9*-124 expression, we found that miR-9/9*-124 



































































































































































































Figure 3. MiR-124 targets both PTBs, but differentially regulate PTB expression during neuronal conversion.
(A) Top, a schematic diagram of PTB 3’UTRs with miR-124 (yellow) and miR-9 (blue) target sites. S1 and s2 refer to the two conserved miR-124 
target sites on PTBP2 3’UTR. Bottom, luciferase assays with luminescence measured after 48 hrs of transfection and normalized to miR-NS control 
in each condition. Data are represented by mean ± SEM from four independent experiments. Two-way ANOVA followed by Dunnett’s test (from left, 
PTBP1 3’UTR ** P = 0.0043, 0.0034; PTBP2 3’UTR * P = 0.0355, ** P = 0.0016)
(B) Top, A heatmap of gene expression assessed by qPCR in starting HAFs, day 30 miRNA-induced neurons (miNs), and human brain RNA. Bottom, 
PTB switching is recapitulated during the miRNA-mediated direct conversion of HAFs into neurons. HAFs and day 30 miNs immunostained for 
37%3DQG37%3DORQJZLWKDILEUREODVWPDUNHU6$DQGDSDQQHXURQDOPDUNHU78%%6FDOHEDU ȝP
(C) Initial induction of PTBP2 by the reduction of PTBP1 by either shRNA or miRNAs during miRNA-mediated neuronal reprogramming. PTBP1 
overexpression in the miR-9/9*-124 expression background suppresses the PTBP2 induction.
(D) Left, an immunoblot showing that PTBP1 knockdown in HAFs resulted in induction of PTBP2, but PTBP2 expression becomes more pronounced 
in the presence of miR-9/9*-124 compared to PTBP1 knowdown only. Right, quantification of PTBP2 band intensity as relative fold changes 
compared to PTBP1 knockdown alone. Data were normalized to HSP90 from four independent experiments. The plots were represented in mean ± 
SEM. One-way ANOVA followed by Tukey’s test (from top *** P = 0.0002, 0.0004; ns P = 0.8925).
(E) Top left, a schematic diagram of the experimental procedure. Right, photographs of day 30 miNs treated with CTL shRNA, PTBP2 shRNA, or 
PTBP2 shRNA with PTBP2 cDNA. Cells were immunostained for PTBP2 and MAP2. Bottom left, quantification of the percentage of MAP2-positive 
FHOOVZLWKWZRRUPRUHQHXULWHSURFHVVHVRYHUWKHWRWDOQXPEHURI'$3,SRVLWLYHFHOOV6FDOHEDU ȝP'DWDDUHUHSUHVHQWHGDVPHDQ6(0
One-way ANOVA followed by Tukey’s test (*** P < 0.0001; ** P 0.0016). shCTL n = MAP2 356/482; shPTBP2 n = MAP2 31/239; shPTBP2+PTBP2 n 
= MAP2 225/454.
(F) A model of differential miR-124 activity on PTB 3’UTRs during neuronal conversion.
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alone condition (Figure 3D). In fact, PTBP2 was more upregulated with miR-9/9*-124 despite 
the more pronounced reduction of PTBP1 with shRNA (Figure 3D), demonstrating that miR-
9/9*-124 accentuate PTBP2 expression beyond the level induced by PTBP1 downregulation.  
Functional significance of PTBP2 expression for neuronal 
conversion 
To probe the functional importance of PTBP2 expression, we knocked down PTBP2 with 
an shRNA during neuronal conversion. PTBP2 shRNA completely impaired the induction of 
neurons marked by the loss of MAP2 expression, a neuronal marker (Figure 3E). The effect of 
shRNA was specific to PTBP2 knockdown as supplementing PTBP2 cDNA rescued the 
reprogramming defect (Figure 3E). These findings were somewhat surprising as the results from 
a previous study indicated that sequential reduction of PTBP2 by shRNA was found to promote 
maturation of reprogrammed neurons (Xue et al. 2016); however, our results indicate that at least 
at the initiation of reprogramming, PTBP2 is critical. While it is not clear why shRNA- versus 
miRNA-based reprogramming approaches lead to these different results, our results demonstrate 
the essential role of PTBP2, at least, at the onset of neuronal conversion. Furthermore, knocking 
down PTBP2 in primary cultured human neurons resulted in increased cell death as measured 
with SYTOX assay (Figure S4A-B), consistent with previous studies that showed the essential 
function of PTBP2 in primary neurons (Li et al., 2014).  
We also performed Human Clariom D Assay in HAFs expressing the non-specific control 
miR-NS, miR-9/9*-124, or miR-9/9*-124 with PTBP2 shRNA to identify genes whose 
expression and alternative splicing patterns were affected by the reduction of PTBP2. By two 
weeks, miR-9/9*-124-expressing cells showed significant downregulation of PTBP1 and other 
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fibroblast-enriched genes such as FBN1 and S100A4, and upregulation of PTBP2 and neuronal 
genes (for example, NEFM, and SNAP25) in comparison to the control miR-NS (FC  ≥ 1.5, 
ANOVA p-value < 0.05) (Figure S4C) (Abernathy et al., 2017). Alternative splicing events 
mediated by PTBP2 were examined by comparing spliced events between PTBP2 shRNA and 
control shRNA (shCTL) conditions. We found that reducing PTBP2 led to changes in splicing 
events (-2 ≤ splicing index ≥ 2, ANOVA p-value < 0.05) indicated by red (positive splicing 
index) and green dots (negative splicing index) (Figure S4D). This analysis identified known 
splicing targets of PTBP2, such as the exon skipping or exclusion in UNC13B, DLG4, and 
CADM3, and inclusion in DNM1 and SMARCC2 transcripts (Figure S4D) (Li et al., 2014; 
Licatalosi et al., 2012; Vuong et al., 2016; Zheng et al., 2012). Comparing genes upregulated in 
response to miR-9/9*-124 to genes associated with PTBP2-mediated alternative splicing 
(differential splicing events between miR-9/9*-124-shCTL and shPTBP2 conditions), identified 
1183 differentially spliced transcripts of genes involved in processes such as neuronal 
differentiation and signaling (Figure S4E) (Table S2). Altogether, our results support the role of 
PTBP2 as a crucial regulator of the neuronal program. 
Differential sequence composition between PTBP1 and PTBP2 
3’UTRs 
Using PTBP1 downregulation and PTBP2 upregulation as a model, we sought to identify 
effectors that determine miR-124 function as a positive regulator. RNA-binding proteins (RBPs) 
have been shown to interact with miRNA-loaded RISC complexes to modulate target gene 
expression (Iadevaia and Gerber, 2015; Jiang and Coller, 2012; Plass et al., 2017). We ran the 
sequence of PTBP2 3’UTR through three RBP motif prediction databases, including RBPDB 
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(Cook et al., 2011), RBPmap (Paz et al., 2014), and beRBP (Yu et al., 2018) (Figure S5A). 
Across the three databases, two RBPs, ELAVL1 and PUM2, were consistently predicted to bind 
to PTBP2 3’UTR (Figure S5A). As PTBP2 upregulation occurs in neurons, we focused on the 
family of RBPs whose expression is neuronally enriched. Whereas ELAVL1 and Pumilio family 
RBPs, PUM2 or its homolog, PUM1, are ubiquitously expressed (Lin et al., 2018; Okano and 
Darnell, 1997; Spassov and Jurecic, 2002), other ELAVL family members, ELAVL2, ELAVL3, 
and ELAVL4 (collectively referred to as neuronal ELAVLs, nELAVLs), have been shown to be 
neuronally enriched (Okano and Darnell, 1997). We also examined the HITS-CLIP data of 
nELAVLs in the human brain (Scheckel et al., 2016) and found nELAVLs to be highly enriched 
at PTBP2 3’UTR, in contrast to PTBP1 3’UTR (Figure S5B-C). Interestingly, PTBP2 3’UTR 
contains AU-rich elements (AREs) that ELAVLs have been shown to bind to (Ince-Dunn et al., 
2012; Scheckel et al., 2016), in contrast to PTBP1 3’UTR that lacks the ARE (Figure S5B). 
Moreover, nELAVL binding mapped to the ARE around the first miR-124 site (s1; seed, 
highlighted in red) PTBP2 3’UTR (Figure S5C). We thus examined by qPCR if nELAVLs are 
induced during neuronal conversion as well as other brain-enriched RBP markers including 
NOVA-, RBFOX-family proteins, and SSRM4. We found selective upregulation of nELAVLs 
with other neuronal RBPs in miNs similarly to the human brain, in contrast to the ubiquitous 
expression of ELAVL1 (Figure 4A) (Okano and Darnell, 1997). To determine if nELAVL 
induction occurs concurrently with PTBP2 upregulation, we assessed ELAVL expression at 
multiple time points of neuronal conversion. We found that the transcriptional activation of 
nELAVLs, with ELAVL3 being the most robust one (blue), aligned with the upregulation of 









































































































































































































































Figure 4. MiRNA-mediated PTBP2 upregulation requires nELAVL binding at PTBP2 3’UTR 
(A) An expression heatmap of neuronal-enriched RBPs determined by qPCR in starting HAFs, day 20 miNs, and human brain RNA.
(B) Time course qPCR assays of PTB and ELAVL transcripts during neuronal reprogramming. 
(C) Left, a diagram of luciferase constructs containing different PTB 3’UTRs: PTBP1 3’UTR, and PTBP2 3’UTR with and without (PTBP2¨ARE) the AU-rich 
element (ARE) used for RIP and luciferase assays. Right, RIP of individual FLAG-tagged ELAVLs 48 hrs after transfection. Enrichment normalized to input 
determined by qPCR for PTBP1 or PTBP2 3’UTR. Data are represented by mean ± SEM from three independent experiments. Two-way ANOVA followed 
by Dunnett’s test (from left, PTBP2 3’UTR *** P = 0.0001, ** P = 0.0086, 0.0042).
(D) Luciferase assays with the addition of individual ELAVLs in the luciferase constructs containing the control PGK1, PTBP1, PTBP2 or PTBP2¨ARE 
3’UTR. Luminescence was measured 48 hrs after the transfection and normalized miR-9/9*-124 to miR-NS control of each condition. Data are represented 
by mean ± SEM from at least three independent experiments. Two-way ANOVA followed by Dunnett’s test (* P = 0.0312, *** P = 0.0001).
(E) Left, a schematic diagrm of ELAVL3 hinge mutants. Right, luciferase assays with the addition of wild-type ELAVL3 or ELAVL3 hinge mutants (ELAVL3¨
H: ELAVL3 hinge deletion; ELAVL3-E1H: ELAVL3 with ELAVL1 hinge). Luminescence was measured 48 hrs after transfection and normalized  
miR-9/9*-124 to miR-NS control of each condition. Data are represented by mean ± SEM from at least four independent experiments. Two-way ANOVA 
followed by Tukey’s test (from left ** P = 0.0020, * P = 0.0435, * P = 0.0286).
(F) Left, a schematic diagram of ELAVL1 hinge mutants. Right, luciferase assays with the addition of wild-type ELAVL1 or ELAVL1 hinge mutants (ELAVL1
¨H: ELAVL1 hinge deletion; ELAVL1-E3H: ELAVL1 with ELAVL3 hinge). Luminescence was measured 48 hrs after transfection and normalized 
miR-9/9*-124 to miR-NS control of each condition. Data represented in mean ± SEM from at least four independent experiments. Two-way ANOVA followed 
by Tukey’s test (** P = 0.0069, * P = 0.0260).
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MiRNA-mediated PTBP2 induction requires ELAVL3 binding at 
PTBP2 3’UTR 
We then tested whether ARE within PTBP2 3’UTR would serve as a sequence that binds 
ELAVL proteins by expressing 3’UTRs of PTBP1, PTBP2, or PTBP2 without ARE 
(PTBP2DARE 3’UTR) with individual FLAG-tagged ELAVLs (ELAVL1-4) in HEK293T cells 
(Figure 4C). RNA-immunoprecipitation (RIP) of FLAG-ELAVLs with FLAG antibody, 
followed by qPCR for detecting the loaded 3’UTRs using primers specific for either PTBP1 or 
PTBP2 displayed significant enrichment for PTBP2 3’UTR with nELAVL (ELAVL2, 3, and 4) 
pull-downs, while the binding of ELAVL1 to PTBP2 3’UTR was minimal. We could not detect 
significant enrichment for PTBP1 3’UTR for any of the ELAVLs (Figure 4C). Importantly, 
deleting ARE in PTBP2 3’UTR (PTBP2DARE 3’UTR) abolished the binding of nELAVL 
proteins to PTBP2 3’UTR (Figure 4C) indicating that ARE within PTBP2 3’UTR serves to 
recruit nELAVLs.  
We then asked whether adding nELAVLs to the non-neuronal context of HEK293T cells, 
thereby reconstituting nELAVLs that become available during neuronal conversion, would 
alleviate miR-124-mediated repression of PTBP2 and enhance PTBP2 expression. Adding 
individual ELAVLs to control PGK1 3’UTR had no effect on luminescence (relative 
luminescence of ~ 1; PGK1 3’UTR histograms) (Figure 4D). Luciferase activities with PTBP1 
3’UTR remained repressed upon miR-9/9*-124 expression compared to the control miR-NS 
irrespective of the ELAVL addition (relative luminescence of < 1; PTBP1 3’UTR histograms) 
(Figure 4D). MiR-9/9*-124 led to the repression PTBP2 3’UTR in the absence of ELAVLs 
(black, relative luminescence ratio < 1; PTBP2 3’UTR histograms) (Figure 4D). However, 
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adding ELAVL2 (green) and ELAVL3 (blue) significantly alleviated miR-9/9*-124-mediated 
repression on PTBP2 3’UTR, with especially ELAVL3 (blue) having the most significant effect 
on elevating the luciferase activity in comparison to the control construct (Figure 4D). To 
examine the requirement of ARE, we repeated the ELAVL addition experiments using the 
luciferase cassette with PTBP2 3’UTR lacking the ARE sequence (PTBP2DARE). Deleting ARE 
abolished the effect of ELAVL3 (blue) on PTBP2 (PTBP2DARE 3’UTR histograms), which 
stayed repressed (Figure 4D), demonstrating the requirement of ELAVL3 and ARE for PTBP2 
upregulation by miR-124.  
Selective activity of ELAVL3 on PTBP2 3’UTR is dependent on the 
hinge region 
ELAVL1-4 members exhibit high sequence homology across all three functional RNA 
recognition motifs (RRMs) except for the non-conserved spacer region (also referred to as hinge 
region) flanked by RRM2 and RRM3 (Hinman et al., 2013; Okano and Darnell, 1997). To better 
understand the specificity of ELAVL3 on PTBP2 3’UTR regulation, we mutagenized the hinge 
region of ELAVL1 and ELAVL3 by deleting or swapping the hinge region (H) between ELAVL1 
and ELAVL3. Deleting the H in ELAVL3 (ELAVL3DH) (light blue) abrogated the alleviating 
effect on PTBP2 3’UTR repression, whereas no effect was observed with PGK1 3’UTR (Figure 
4E, PGK1 3’UTR histograms). Moreover, replacing the ELAVL3 H with ELAVL1 H (ELAVL3-
E1H) (dark blue) led to the failure of alleviating the PTBP2 3’UTR repression (Figure 4E), and 
none of the ELAVL3 variants (wild-type and mutants) had any effect on PTBP2DARE 3’UTR 
(Figure 4E, PTBP2DARE 3’UTR histograms). These results indicate that the specificity of 
ELAVL3 to PTBP2 3’UTR is mediated by the ELAVL3 H region. This notion is further 
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supported by the increase in the luminescence readout of PTBP2 3’UTR in HEK293T cells when 
ELAVL1 H is replaced by ELAVL3 H (ELAVL1-E3H) (dark red) compared to wild-type ELAVL1 
(red) (Figure 4F, PTBP2 3’UTR histograms).  
ELAVL3 promotes PTBP2 expression during neuronal 
reprogramming 
To further examine if ELAVL3 would be critical for PTBP2 upregulation during the 
neuronal conversion of HAFs, we knocked down ELAVL3 by shRNA (shELAVL3) to assess 
PTBP2 expression and neuronal reprogramming. Knocking down ELAVL3 resulted in the 
significant downregulation of PTBP2 expression as determined by immunostaining, qPCR, and 
immunoblotting analyses, and impairment of the conversion process (Figures 5A-C). This 
knockdown effect was specific for ELAVL3 downregulation as PTBP2 expression and neuronal 
fate acquisition could be rescued by overexpressing ELAVL3 cDNA in the presence of shELAV3 
(Figure 5A). It is noteworthy that reducing the function of other nELAVLs (ELAVL2 and 4) had 
a milder effect on PTBP2 expression (Figures 5B-C), highlighting the role of ELAVL3 as a 
primary driver for PTBP2 upregulation with miR-124.  
Synergism between nELAVL and AGO requires miR-124 site in 
PTBP2 3’UTR 
We further tested whether the miR-124 sites within PTBP2 3’UTR would also be critical 
for mediating the PTBP2 upregulation with ELAVL3. By mutating the miR-124 seed-match 
sequences within PTBP2 3’UTR (PTBP2Ds1s2 3’UTR), adding ELAVLs failed to enhance the 



























































































































































































































Figure 5. PTBP2 upregulation requires the synergism of nELAVL and miR-124
(A) Left, day 30 miNs with shRNA knockdown against CTL, ELAVL3, and ELAVL3 with ELAVL3 cDNA rescue. Cells were immunostained for 
0$3DQG37%36FDOHEDU ȝP5LJKWTXDQWLILFDWLRQRIWKHSHUFHQWDJHRI0$3SRVLWLYHFHOOVRYHUWKHWRWDOQXPEHURI'$3,SRVLWLYH
cells with two or more neurites (left). Data represented as mean ± SEM. One-way ANOVA followed by Tukey’s test (from left, *** P < 0.0001, 
*** P < 0.0001). shCTL n = MAP2 803/1060; shELAVL3 n = MAP2 67/1052; shELAVL3 + ELAVL3 n = MAP2 431/617.
(B) Left, immunoblot analysis of PTBP2 in day14 miNs with knockdown against CTL, ELAVL2, ELAVL3, and ELAVL4. Right, quantification of 
the PTBP2 band intensity as a relative fold change compared to shCTL normalized to HSP90 in four independent experiments. Data are 
represented by mean ± SEM. One-way ANOVA followed by Dunnett’s test (* P = 0.0422).
(C) The relative quantity of PTBP2 transcript upon individual nELAVL knockdown compared to CTL at day14 miNs determined by qPCR. 
Data are represented by mean ± SEM from 3 independent experiments. One-way ANOVA followed by Dunnett’s test (*** P = 0.0001).
(D) Top, a diagram of luciferase constructs containing PTBP2 3’UTR with or without miR-124 sites (PTBP2¨s1s2). Bottom, luciferase assays 
with the addition of individual ELAVLs in PGK1 control, PTBP2, or PTBP2¨s1s2 3’UTR. Luminescence was measured 48 hrs after 
transfection and normalized miR-9/9*-124 to miR-NS control of each condition. Data are represented by mean ± SEM from at least three 
independent experiments.Two-way ANOVA followed by Dunnett’s test (* P = 0.0312, *** P = 0.0001).
(E) RIP of individual FLAG-tagged ELAVLs in PTBP2¨s1s2 3’UTR 48 hrs after transfection. Enrichment normalized to input determined 
through qPCR against PTBP2 3’UTR. Data are represented by mean ± SEM from three independent experiments. Two-way ANOVA 
followed by Dunnett’s test (from left, PTBP2¨s1s2 3’UTR ** P = 0.0018, *** P = 0.0001, *** P = 0.0001).




















PTBP2Ds1s2 3’UTR histograms) (Figure 5D). This result is in contrast to wild-type PTBP2 
3’UTR where ELAVL3 can enhance luciferase activity in the presence of miR-124 target sites 
(Figures 4D, 5D). Interestingly, the lack of the increased luminescence with ELAVL3 addition 
was not due to the failure of ELAVL binding to PTBP2Ds1s2 3’UTR because qPCR analysis 
with nELAVL-RIP showed persistent binding of ELAVLs to PTBP2Ds1s2 3’UTR (Figure 5E). 
These results altogether suggest the requirement of both ARE and miR-124 sites in PTBP2 
3’UTR for PTBP2 upregulation (Figure 5F).  
Neuronal genes are downregulated upon loss of miR-124 and 
ELAVL3 in human neurons 
To test whether the synergism of miR-124 and ELAVL3 for miRNA-mediated 
upregulation is unique to PTBP2 or a broader mechanism applicable to other genes beyond 
reprogrammed neurons, we performed loss-of-function studies on primary human neurons 
(HNs). With the same TuD-miR-124 and shELAVL3 constructs used in reprogrammed neurons, 
miR-124 and ELAVL3 were knockdown in HNs and processed for RNA-seq (Figures 6A-B and 
S6A). To identify potential targets upregulated by miR-124 and ELAVL3 in HNs, we focused on 
genes suppressed upon expression of TuD-miR-124 and shELAVL3 (KD, Log2FC ≤ -1; adj.P-
value < 0.05) compared to CTL (Figure 6B). Many of these downregulated genes are neuronal-
related, including MAP2, PTBP2, SCN1A, and SEMA6A (Figure 6B). Despite the downregulation 
of several neuronal transcripts, overall neuronal identity remains intact as expression of neuronal 
markers such as RBFOX2, FMR1, and NEFL remain similar between CTL and KD HNs (Figure 
S6B). Furthermore, we also do not observe an emergence of progenitor marker expression upon 


































































































































































To ensure that these downregulated genes are miR-124 targets, we compared the 
downregulated DEGs from HNs to upregulated DEGs in day 20 miNs that also harbor AGO-
enriched peaks (Figure 1). This comparison resulted in a set of 132 target genes associated with 
biological GO terms related to neuronal development and projection (Figure 6C, Table S3), 
further validating miR-124 as a positive regulator of the neuronal program. Examples of some 
these identified targets in HNs also validated in qPCR include PTBP2, MAP2, SEMA6A, SCN1A, 
and KALRN (Figures 6D-F). Together our data support the notion that miR-124-mediated 
upregulation of neuronal genes is not unique to PTBP2 in reprogramming context, but applicable 
to other neuronal genes in actual human neurons. 
MiR-124 and nELAVL interaction for other neuronal transcripts 
Using existing nELAVL HITS-CLIP of the human brain (Scheckel et al., 2016), we 
performed a comparative analysis with our HNs dataset to examine if these upregulated neuronal 
transcripts are likely targets of nELAVLs. First, by overlapping i) upregulated neuronal DEGs 
bound by AGO HITS-CLIPs (Figure 1), ii) DEGs responsive to miR-124 tough decoy and 
ELAVL3 shRNA in HNs (Figure 6), and iii) genes bound by nELAVLs in the human brain 
(Scheckel et al., 2016), we identified 77 genes, including PTBP2, MAP2, SLCA48, KALRN, 
BCL7A, and SCN1A enriched for neuronal biological terms generally involved in synaptic 
processes (Figures 6G and S7, Table S4). Based on these comparisons, similar to what we 
observed in miNs, miR-124 and ELAVL3 appear to collectively upregulate a set of neuronal 
genes that are likely critical for neuronal function in primary HNs.  
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Neuronal properties affected by miR-124 and nELAVLs 
As our AGO-HITS-CLIP and miR-124 knockdown data in miNs indicate that neuronal 
genes are preferentially targeted as cells acquire the neuronal fate (Figures 1 and 2), we 
examined the global transcriptome changes of our knockdown (KD) and control (CTL) 
conditions in HNs with LONGO analysis to assess changes in long gene expression (LGE), a 
measure of neuronal identity and maturation (Gabel et al., 2015; King et al., 2013; McCoy et al., 
2018; McCoy and Fire, 2020; Sugino et al., 2014). Overall, knockdown of miR-124 and 
ELAVL3 (KD, green) in HNs resulted in reduced LGE compared to control (CTL, red), 
suggesting that both players are likely essential for the expression of long genes (Figure 7A).  
As a number of identified neuronal genes targeted by AGO-miR-124 and ELAVL3 in 
HNs are implicated in neuronal function and morphology such as SCN1A, SLC4A8, ANK3, and 
MAP2, reflective of reduced overall LGE (Figures 7A and S7A, Table S4), we examined a few 
neuronal properties in CTL and KD HNs. We first performed electrophysiology and found KD 
HNs exhibited reduced inward sodium current as compared to CTL HNs (Figures 7B and S6C-
D) which we reasoned to be attributed to a number of downregulated channel genes in KD HNs. 
However, other electrical properties such as resting membrane potential and action potential 
firing appear similar between CTL and KD HNs (Figures S6D-E). In addition, as we observed 
reduced neurite complexity in our KD cells compared to CTL HNs, we sought to measure 
features such as average neurite length and average number of neurite branches between the two 
conditions. Overall, we found that KD HNs not only have shorter average neurite length per cell, 
but also have fewer branches per cell compared to CTL (Figures 7C-E). 
 Reduced LGE in primary HNs with both miR-124 and ELAVL3 knockdown suggests 




Figure 7. Long gene dysregulation results in altered neuronal properties
(A) LONGO plot showing reduced long gene expression upon knockdown of miR-124 and ELAVL3 (KD; green) compared to CTL (red). Lines 
show mean gene expression and ribbons show standard error of the mean (SEM).
(B) Left, voltage-clamp traces of CTL and KD (TuD-miR-124 and shELAVL3) HNs. Right, average I-V curve of for all recorded CTL and KD HNs. 
Data are represented in ± SEM from seven recorded cells from each condition. Two-tailed unpaired t-test (from left, ** P = 0.00434 ; ** P < 
0.00681 ; * P = 0.01233).
(C) Representative images of CTL and KD HNs marked by TurboRFP reporter. Processed images by CellProfiler to identify neurites and 
associated cell soma. 6FDOHEDU ȝP
(D) Left, mean neurite length measurement of CTL and KD HNs. Data are represented in ± SEM from seven separate fields of view; CTL n = 
768, KD n = 677. Two-tailed unpaired t-test (** P = 0.0092). Right, mean number of neurite branches in CTL and KD HNs. Data are represented 
in ± SEM from seven separate fields of view; CTL n = 768, KD n = 677. Two-tailed unpaired t-test (** P = 0.0038).
(E) Representative images of primary rat neurons stained for MAP2 after treatment with DMSO control or Topotecan (TOPO).
(F) LONGO plot showing reduced long gene expression upon treatment with TOPO (blue) compared to DMSO (red) in primary rat neurons. Lines 
show mean gene expression and ribbons show standard error of the mean (SEM).
(G) Expression of a select unaffected neuronal markers between DMSO and TOPO treatments.
(H) MEA readout for mean firing rate, burst frequency, and spikes per bursts of primary rat neurons treatment with DMSO or TOPO. 
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measured in HNs. To independently validate the correlation between LGE and neuronal 
maturity, we also treated primary rat neurons with Topotecan (TOPO), an inhibitor of 
Topoisomerase I known to reduce LGE in neurons (King et al., 2013; Mabb et al., 2016, 2014). 
Primary rat neurons treated with TOPO (blue) were found to display a reduction in LGE when 
compared to the control condition (DMSO, red) (Figures 7E-F) while the TOPO-treated cells still 
maintained the expression of other neuronal markers such as Map2, Actl6b, Rbfox3 and Dcx 
(Figure 7G). To further assess the consequences of LGE reduction in neurons, we measured 
electrophysiological properties using a microelectrode array (MEA). TOPO-treated neurons 
exhibited altered electrophysiological properties compared to DMSO control, including reduced 
mean firing rate, mean burst frequency, and number of spikes per burst (Figures 7H-I), 
demonstrating that LGE is a transcriptomic feature related to the functional maturity of neurons. 
Therefore, our results support the notion that miR-124, in synergy with ELAVL3, promote 
neuronal maturity by positively regulating their target genes, as evidenced by their effect on LGE 
in human neurons. Based on PTBP2, we delineated a mechanism on how miR-124 and ELAVL3 
can promote the expression of their targets and we anticipate that some of the additional 
identified long genes important for neuronal differentiation and function are likely upregulated in 
a similar manner.  
Materials and Methods 
Cell culture 
Primary human fibroblasts used in this study was from a 22-year-old female (GM02171, 
NIGMS Coriell Institute for Medical Research) while human neonatal fibroblasts (ScienCell, 
2310) was used exclusively for the HITS-CLIP experiment. Fibroblasts were maintained in high 
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glucose Dulbecco’s Modified Eagle Medium (Gibco, 11960044) containing 10% FBS (Gibco, 
10437028), MEM non-essential amino acids (Gibco, 11140050), sodium pyruvate (Gibco, 
11360070), GlutaMAX (Gibco, 35050061), HEPES (Gibco, 15630080), penicillin-streptomycin 
(Gibco, 15130122), and 2-mercaptoethanol (Gibco, 21985023) at 37°C. Primary human neurons 
were obtained commercially (ScienCell, 1520) with gender and age of the source undisclosed 
Human neurons were maintained in neuronal media (NM; ScienCell, 1521) at 37°C. E18 rat 
cortex (BrainBits®, FSDECX1M) were grown in STEMdiffTM Neural Induction Medium 
(STEMCELL Technologies, 05835). 
 Lenti-X 293T (Clontech, 632180) cells were maintained in high glucose Dulbecco’s 
Modified Eagle Medium (Gibco, 11960044) containing 10% FBS (Gibco, 10437028), MEM 
non-essential amino acids (Gibco, 11140050), sodium pyruvate (Gibco, 11360070), GlutaMAX 
(Gibco, 35050061), HEPES (Gibco, 15630080), penicillin-streptomycin (Gibco, 15130122), and 
2-mercaptoethanol (Gibco, 21985023) at 37°C. 
-streptomycin (Gibco, 15130122), and 2-mercaptoethanol (Gibco, 21985023) at 37°C. 
MiR-9/9*-124-mediated neuronal conversion 
To initiate reprogramming, doxycycline-inducible pT-BclXL-miR-9/9*-124 (Addgene, 
60857) and reverse tetracycline-controlled transactivator rtTA (Addgene, 66810) lentivirus with 
8 ug/mL polybrene (Sigma, H9268) was added to a plate of confluent fibroblasts and spinfected 
at 37°C for 30 min at 1,000xG. Full media change with 1 µg/mL doxycycline (DOX; Sigma-
Aldrich, D9891) occurred the following day. Two days following transduction, cells underwent 
another media change supplemented with DOX and respective antibiotics (Puromycin, Life 
Technologies, A11138-03; Blasticidin S HCl, Life Technologies, A11139-03). Five days after 
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transduction, cells were plated onto poly-l-ornithine (Sigma-Aldrich, P4957), fibronectin 
(Sigma-Aldrich, F4759), and laminin (Sigma-Aldrich, L2020) coated coverslips or onto 10cm2 
Primaria plates (Corning, 353803) followed by full media switch to neuronal media (NM; 
ScienCell, 1521) the next day supplemented with 200 µM dibutyl-cyclic AMP (cAMP; Sigma-
Aldrich, D0627), 1 mM valproic acid (VPA; Sigma Aldrich, P4543), 10 ng/mL human BDNF 
(PeproTech, 450-02), 10 ng/mL human NT-3 (Peprotech, 450-03), 1 µM retinoic acid (RA; 
Sigma-Aldrich, R2625), RevitaCell supplement (Gibco, A2644501), and antibiotics. DOX was 
supplemented every 2 days while half media changes occurred every 4 days until day 30.  
Plasmids and cloning 
For luciferase assay, full length 3’UTR of target transcripts were cloned and ligated into 
pmirGLO vector. For mutagenizing miR-124 target sites, QuikChange XL site-directed 
mutagenesis kit (Agilent, 200516) was used according to the manufacturer’s protocol. Using the 
same UTR sequences, 3’UTR was attached immediately downstream of a destablized EGFP 
reporter and subcloned into lentiviral vector. Sequences for shRNAs were synthesized through 
Integrated DNA Technologies, annealed, and ligated into the pLKO.1 vector (Addgene, 8453 or 
26655). Overexpression vectors of either lentiviral (N106 or N174) or mammalian expression 
(pcDNA3.1+, Invtrogen, V79020) was cut using NotI cut site (NEB, R0189) for insert ligation. 
Tough decoy for miR-124 was synthesized (GeneScript) and subcloned into pLemir vector using 
MluI (NEB, R0198) and NotI sites. 
Lentivirus production 
Lentivirus was produced as previously described (Richner et al., 2015). Briefly, 1.5 µg 
pMD2.G, 4.5 µg psPAX2, 6 µg of plasmid in lentiviral backbone, 600 µl Opti-MEM (Life 
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Technologies, 31985) and 48 µl of 2 mg/mL polyethyleneimine (PEI; Polysciences, 24765) were 
mixed and transfected into Lenti-X 293T (Clontech, 632180) plated at 6x106 cells per 10 cm2 
dish. Media was changed the following day, and viral supernatant was collected, filtered and 
spun at 70,000xG for 2 hr at 4°C two days later. The viral pellet collected per 10 cm2 dish was 
resuspended in 1 mL PBS.  
Immunostaining analysis 
Cells were fixed with 4% paraformaldehyde (PFA; Electron Microscopy Sciences, 
15710) for 20 mins at room temperature (RT) followed by three washes with PBS. Cells were 
permeabilized and blocked in 0.3% TritonX-100, 2% normal goat serum (NGS; Jackson 
ImmunoResearch Laboratories, 005-000-121) and 5% bovine serum albumin (BSA; Sigma-
Aldrich, A7906) in PBS for 1 hr at RT prior to incubation with primary antibodies overnight at 
4°C. After three washes with PBS, cells were incubated with respective secondary antibodies for 
1 hr at RT. Coverslips were mounted onto coverslides with ProLong Gold antifade reagent 
(Invitrogen, P36934) for imaging using Leica SP5X white light laser confocal system with Leica 
Application Suite (LAS) Advanced Fluorescence. See Supplemental Table S4 for a list of 
antibodies used. 
SYTOX assay 
SYTOX assay was performed as previously described (Victor et al., 2018). Briefly, 0.1 
µM SYTOX gene nucleic acid stain (Invitrogen, S7020) and 1 µl/mL of Hoeschst 33342 
(Thermo Scientific, 66249) were added into cell medium. Samples were incubated for at least 15 
mins in 37°C prior to imaging. Images were taken using Leica DMI 4000B inverted microscope 




HEK 293 cells plated in 96-well plate were transfected with 100 ng of pSilencer-miRNA, 
100 ng of pmirGLO containing 3’UTR of interest, and PEI (Polysciences, 24765) with Opti-
MEM (Life Technologies, 31985). Forty-eight hours after transfection, luciferase activity was 
assayed using Dual-Glo luciferase assay system (Promega, E2920) according to the 
manufacturer’s protocol using Synergy H1 Hybrid plate reader (BioTek). Luciferase activity was 
obtained by normalizing firefly luminescence to renilla luminescence (luciferase activity = 
firefly/renilla) followed by normalizing to respective pSilencer-miR-NS control.  
Flow cytometry  
Destabilized EGFP reporter with or without 3’UTR of interest was transduced into HEK 
293 cells to establish a stable reporter containing cell line with Blasticidin S HCl (Life 
Technologies, A11139-03) selection. The day following transduction with miR-9/9*-124 
lentivirus, media was changed with the addition of DOX (Sigma-Aldrich, D9891). At day 3, 
media change was supplemented with DOX and puromycin (Life Technologies, A11138-03). 
DOX was supplemented every 2 days following transduction. At day 10, cells were imaged, and 
collected for flow cytometry. Briefly, cells were collected in PBS and incubated with propidium 
iodide (PI; Sigma-Aldrich, P4861) on ice until ready. Using FACSCalibur (BD Biosciences), all 
PI-negative cell population was obtained for the gating of GFP-negative and -positive cell 
population. 
Quantitative reverse transcription PCR 
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Total RNA of cells was extracted using TRIzol Reagent (Invitrogen, 15596026). Reverse 
transcription was performed using SuperScript III first strand synthesis system for RT-PCR 
(Invitrogen, 18080-051) according to the manufacturer’s protocol from fibroblasts, 
reprogrammed neurons, and human brain total RNA (Invitrogen, AM7962). Quantitative PCR 
was performed using SYBR Green PCR master mix (Applied Biosystems, 4309155) and 
StepOnePlus Real-Time PCR system (Applied Biosystems, 4376600) according to the 
manufacturer’s protocol against target genes. 
HITS-CLIP  
AGO HITS-CLIP was performed on cells after 2 weeks into reprogramming of miR-NS 
or miR-9/9*-124-expressing neonatal fibroblasts (ScienCell, 2310) at day 14 and day 21. Cells 
were harvested, UV-crosslinked, lysed, and processed according to Moore et al. 2014. Briefly, 
cross-linked cells were lysed and treated with RQ1 DNase (Promega, M6101) and RNaseA 
(Thermo). Complex containing AGO-miRNA-mRNA were immunoprecipitated overnight at 4°C 
with pan-AGO antibody. The immunoprecipitated complex was radio-labelled and extracted 
after running on NuPAGE gel (Thermo). RNA from the 130kDa band was extracted for 
sequencing using TruSeq Small RNA Library Preparation Kits (San Diego, CA). Samples were 
sequences using Illumina HiSeq 2500 platform at the Genome Technology Access Center 
(GTAC) at Washington University School of Medicine, St. Louis.  
MiRNA Tough Decoy RNA-seq 
Total RNA was extracted from day 20 cells expressing miR-9/9*-124 + TuD-miR-NS, 
and miR-9/9*-124 + TuD-miR-124 using TRIzol Reagent (Invitrogen, 15596026) in 
combination with RNeasy micro kit (Qiagen, 74004). RNA quality (RIN ≥ 9.6) was determined 
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with 2100 Bioanalyzer (Agilent) and samples underwent low input Takara-Clontech SMARTer 
kit (Takara, 639490) library preparation. Samples were sequenced using NovaSeq S4 and 
processed at the Genome Technology Access Center (GTAC) at Washington University School 
of Medicine, St. Louis. For human neurons, total RNA was extracted from HNs after 8 days of 
tough decoy and shRNA treatment using TRIzol Reagent (Invitrogen, 15596026) in combination 
with RNeasy micro kit (Qiagen, 74004). RNA quality (RIN ≥ 8.4) was determined with 2100 
Bioanalyzer (Agilent) and samples underwent TruSeq Stranded total RNA sequencing kit library 
preparation. Samples were sequenced using NovaSeq6000 through DNA Link (San Diego, CA). 
Human Clariom D Microarray 
For Human Clariom D Array (Affymetrix), total RNA was extracted from day 14 cells 
expressing miR-NS, miR-9/9*-124 + shCTL, and miR-9/9*-124 + shPTBP2 using TRIzol 
Reagent in combination with RNeasy mini kit (Qiagen, 74104). RNA quality (RIN > 9.6) was 
determined with 2100 Bioanalyzer and samples (biological duplicates each) underwent 
amplification and hybridization according to manufacturer’s protocol by GTAC at Washington 
University School of Medicine, St. Louis.  
Immunoblot analysis 
Cells were lysed with sonication (Diagenode, UCD-200) in RIPA buffer (Thermo 
Scientific, 89900) supplemented with protease inhibitor cocktail tablet (Roche, 04693132001). 
Protein concentration of cleared lysate was measured using Pierce BCA protein assay kit 
(Thermo Scientific, 23227) and read with Synergy H1 Hybrid plate reader (BioTek). Lysate and 
sample buffer (Life Technologies, NP0008) were boiled, separated with Bis-Tris gels, and 
transferred to nitrocellulose membrane (GE Healthcare Life Sciences, 10600006). Membrane 
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was blocked with 5% milk for 1 hr at RT and incubated with primary antibody overnight at 4°C. 
After three washes of TBST (1X TBS and 0.1% Tween-20), the membrane was incubated with 
respective horseradish peroxidase-conjugated antibody for 1 hr at RT followed by three washes 
with TBST. Blots were developed with ECL system (Thermo Scientific, 34580) and imaged or 
developed onto film. See Supplemental Table S3 for a list of antibodies used. 
Immunoprecipitation analysis 
Cells were lysed with sonication (Diagenode, UCD-200) in IP buffer (20 mM HEPES, 
150 mM NaCl, 10% glycerol, 5 mM EDTA, 1% Triton X-100) supplemented with protease 
inhibitor cocktail tablet (Roche, 04693132001). Cleared lysate was incubated with anti-FLAG 
M2 magnetic beads (Sigma-Aldrich, M8823) overnight with rotation at 4°C. The beads were 
washed three times with IP buffer and bound proteins were boiled and eluted with sample buffer 
(Life Technologies, NP0008), separated with Bis-Tris gels, and immunoblotted.  
RNA-IP 
Cells were lysed with sonication (Diagenode, UCD-200) in IP buffer (20 mM HEPES, 
150 mM NaCl, 10% glycerol, 5 mM EDTA, 1% Triton X-100) supplemented with protease 
inhibitor cocktail tablet (Roche, 04693132001). Cleared lysate was incubated with anti-FLAG 
magnetic beads (Sigma-Aldrich, M8823) overnight with rotation at 4°C beads. The beads were 
washed three times with IP buffer and resuspended in 90 ul of IP buffer with proteinase K (NEB, 
P8107S) for 30 mins at 37°C. To extract RNA, 1 mL of TRIzol Reagent (Invitrogen, 15596026) 





Whole-cell patch-clamp recordings were performed as previously described (Victor et al., 
2018). Briefly, HNs (ScienCell, 1521) were recording within 8 to 10 days after tough decoy and 
shRNA transduction. Recordings were acquired using pCLAMP 10 software, multipliclamp 
700B amplifier, and Digidata 1550 digitizer (Molecular Devices, CA). Glass electrode pipettes 
were pulled from borosilicate glass (1B120F-4, World Precision) to obtain pipette resistance 
ranging from 5 – 8 MΩ using next generation micropipette puller (P-1000, Sutter Instrument). 
External solution is consist of 140 mM NaCl, 3 mM KCl, 10 mM Glucose, 10 mM HEPES, 2 
mM CaCl2 and 1 mM MgCl2, and internal solution is consist of 130 mM K-Gluconate, 4 mM 
NaCl, 2 mM MgCl2, 1 mM EGTA, and 10 mM HEPES (adjusted to pH 7.25 with KOH) were 
used for recording. For all recordings, the membrane potentials were held at -65 mV. 
Microelectrode array 
E18 rat cortical neurons (BrainBits, FSDECX1M) were plated onto a 24-well cell culture 
microelectrode array plate (Axion Biosystems, M384-tMEA-24W). Prior to plating, 1 ml of 
sterile water and 10 µl of PEI (Sigma-Aldrich, 03880) at 0.5% diluted in 0.1 M HEPES pH 8.0 
(Caymen Chemical Company, 700014) was added to the center of each well. After incubating 
overnight at 37 °C, each well was washed 4x with sterile water, and allowed to dry for 15 
minutes. 10 µl of Laminin (Sigma-Aldrich, L2020) at 10 µg/mL diluted in cold DMEM/F-12 
(ThermoFisher, 11320082) was added to each well and incubated at 37 °C for 2 hours. Laminin 
was aspirated prior to plating neurons. 24 hours after plating, neurons were cultured in BrainPhys 
Neuronal Medium and SM1 supplement (STEMCELL Technologies, 05792) with either 
Topotecan (Sigma-Aldrich, T2705) at a final concentration of 300 nM in DMSO (0.05% DMSO 
51 
 
final concentration) or DMSO control for one week before recording electrophysiological 
activity using a Maestro MEA plate reader (Axion Biosystems). 
GO enrichment analysis 
Gene ontology analyses were performed using Metascape (Tripathi et al., 2015) with 
minimum overlap of 3, P-value cutoff of 0.01, and minimum enrichment of 1.5. Entire gene list 
was used for each GO analysis. 
RNAhybrid miRNA-target duplex analysis 
To predict the presence of miR-124-3p binding sites at HITS-CLIP peaks, peak 
sequences were extracted by on the genomic coordinates and processed through RNAhybrid 
(Rehmsmeier, 2004) against miR-124-3p miRNA sequence with at least a free energy threshold 
of -20 kcal/mol. 
RBP binding analysis 
RNA-binding protein prediction database/software, RBPDB (Cook et al., 2011), RBPmap 
(Paz et al., 2014), and beRBP (Yu et al., 2018) for PTBP2 3’UTR sequence were used. Default 
criteria were selected for all three software for non-bias prediction of any human RBP motifs.  
Neurite length measurement 
Images of HNs marked by TurboRFP were processed through CellProfiler 3.1.9 (McQuin 
et al., 2018). Briefly, neurite feature was enhanced prior to the identification of primary object or 
soma between 25 – 100 pixel unit in diameter, followed by the identification of secondary object 
based on neurite feature. A morphological skeleton was made based on overlaying the identified 
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objects and mean neurite lengths and branches were then measured using measure object 
skeleton module. 
LONGO analysis 
LGE for human and rat neurons were determined by through the LONGO platform 
(McCoy et al., 2018) . LONGO analysis output of gene expression (CPM) over gene length was 
used to generate the LONGO plot. 
Data Analyses 
AGO HITS-CLIP reads for miR-NS and miR-9/9*-124-expressing cells at least two 
weeks into reprogramming were trimmed and aligned to human genome hg38 using STAR with 
default parameters. Differential peaks between miR-9/9*-124 and miR-NS conditions were 
detected using MACS (Feng et al., 2012; Zhang et al., 2008) with the following criteria: mfold 
bound of 5 – 50, fragment size of 100, and FDR > 0.05. HITS-CLIP datasets will be publicly 
available. 
RNA-seq for day 20 miNs expressing either CTL TuD-miR-NS or TuD-miR-124 was 
analyzed by GTAC’s RNA-seq pipeline. Briefly, reads were aligned to hg38 with STAR and 
processed through EdgeR (Robinson et al., 2010) to obtain differentially expressed genes with 
adj. p-value of < 0.05. RNA-seq dataset consisting of TuD-miR-NS and TuD-miR-124 at day 20 
will be publicly available. 
RNA-seq for HNs treated with either CTL or tough decoy against miR-124 and shRNA 
against ELAVL3 (KD) was aligned through Partek® Flow® software (Partek Inc., 2020) to 
generate gene counts. Briefly, reads were aligned to hg38 with STAR and processed through 
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EdgeR (Robinson et al., 2010) to obtain differentially expressed genes with adj. p-value of < 
0.05 and Log2FC of ≤ -1 and ≥ 1. RNA-seq dataset consisting of CTL and KD treatments from 
HNs will be publicly available. 
RNA-seq for primary rat neurons treated with either DMSO or Topotecan (TOPO) were 
aligned to the Ensembl release 76 top-level assembly with STAR. Transcript counts were 
produced by Sailfish version 0.6.3. All gene-level and transcript counts were then imported into 
the R/Bioconductor package EdgeR and TMM normalization size factors were calculated to 
adjust samples for differences in library size. RNA-seq dataset consisting of DMSO and TOPO 
treatments from rat neurons will be publicly available. 
Human Clariom D Array data was analyzed using manufacturer’s software, Expression 
Console followed by Transcriptome Analysis Console (TAC). For gene level analysis, genes 
comparing miR-9/9*-124 vs miR-NS linear fold change of  ≥ 1.5 and ANOVA P < 0.05 were 
considered to upregulated in neuronal conditions. For splicing analysis, splicing events with 
linear splicing index ≤ -2 and ≥  2, ANOVA P < 0.05 were considered significant splicing events. 
Human Clariom D array dataset consisting of miR-NS, miR-9/9*-124 with shCTL, and miR-
9/9*-124 with shPTBP2 at day 14 will be publicly available. 
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Figure S2. Examples of RNAhybrid prediction of miR-124-3p hybridization to enriched 3’UTR HITS-CLIP peak sequences of day 20 upregulated 
DEGs in miNs
(A) KALRN contains one enriched AGO HITS-CLIP peak for miR-124-3p at 3’UTR highlighted in yellow.
(B) BCL7A 3’UTR contains two predicted miR-124-3p sites within the AGO HITS-CLIP peaks highlighted in yellow. 
(C) RCAN2 and SEMA6A 3’UTRs contain multiple miR-124-3p target sites within the AGO HITS-CLIP peaks highlighted in yellow. 
GGU    AU    ACC       GUGUGCCUU
G       CC    AA       CGA                       U SEMA6A 5’
miR-124-3p 3’
CCG    UA    UGG       CGCACGGAA
AA                AG                                     U
-24.6 kcal/mol
CACUGUGUGU
C                          G SEMA6A 5’
miR-124-3p 3’
 GUGGCGCACG
AACCGUAA                          GAAU
-21.0 kcal/mol
UUG  GUU  CA   CUGUG          GCCU
G       G        A     U              AAUA           G SEMA6A 5’
miR-124-3p 3’
ACC  UAA   GU  GGCGC          CGGA
A        G                               A                   AU
-23.3 kcal/mol
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miR-124-3p 3’
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-21.3 kcal/mol
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miR-124-3p 3’
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Figure S3. MiR-124 target site validation, and assessment of miR-124 promoting PTBP2 expression via targetting PTBP2 3’UTR with the 
prolonged neurogenic input.
(A) Luciferase assays in HEK293T cells of PTBP2 3’UTR with miR-124 site(s) mutagenized. Luminescence was measured 48 hrs after 
transfection and normalized to miR-NS control of each condition. Data are represented by mean ± SEM from four independent experiments. 
Two-way ANOVA followed by Dunnett’s test (from left, miR-124 ** P = 0.001; miR-9/9*-124 * P = 0.0104, *** P = 0.0001). 
(B) Left, a schematic diagram of the reporter construct and experiments. HEK293T cells were transduced with destabilized EGFP reporter to 
monitor the 3’UTR activity. Right, representative images of GFP fluorescence of HEK293T cells measured 10 days after miR-9/9*-124 
transduction. 6FDOHEDU ȝP
(C) Left, schematic of a histogram of flow cytometry analysis with gating of EGFP intensity to separate GFP-negative and GFP-positive cell 
populations at day 10. Middle, representative images of histograms following flow cytometry. Right, quantification flow cytometry to determine 
percent GFP-positive, PI-negative cells over the total PI-negative cells. Data represented in mean ± SEM from five independent experiments. 
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Figure S4. PTBP2 plays an essential role during miRNA-mediated neuronal conversion
(A) A schematic diagram of SYTOX assay. Knockdown of PTBP2 with shRNA in primary human neurons resulted in increased cell death measured by 
SYTOX after 10 days. 
(B) Left, representative images of phase contrast and SYTOX staining 10 days after knockdown with CTL or PTBP2 shRNA. Right, 
TXDQWLILFDWLRQRI6<72;SRVLWLYHFHOOVRYHUWRWDO+RHFKVWSRVLWLYHFHOOV6FDOHEDU ȝP'DWDDUHUHSUHVHQWHGE\PHDQ6(0VK*)3
n = SYTOX 1237/2073; shPTBP2 n = 1589/1759 scored from independent fields of view. Unpaired t-test (*** P = < 0.0001).
(C) A volcano plot comparing gene expression between miR-9/9*-124 and miR-NS expression on day 14. Red dots within the enclosed box indicate 
GLIIHUHQWLDOO\H[SUHVVHGJHQHVIROGFKDQJH$129$SWKDWDUHXSUHJXODWHGLQPL5FRQGLWLRQ([DPSOHVRIQRQQHXURQDODQG
neuronal genes are highlighted in green and red dots, respectively.
'$YROFDQRSORWRIGLIIHUHQWLDOO\VSOLFHGHYHQWVVSOLFLQJLQGH[$129$3DWGD\FRPSDULQJVK37%3WRVK&7/LQWKHPL5
expression background. Examples of spliced targets are highlighted with gene names corresponding to the differential splicing events.
(E) Top, target genes of interest were obtained by overlapping upregulated neuronal-associated events in (C) to all differentially spliced events by 










































































PTBP1 3’UTR: (first 500bp:39% AT-rich, entire: 56% AT-rich)









Figure S5. nELAVLs bind preferentially to PTBP2 and not PTBP1 3’UTR in the human brain
(A) Left, a Venn diagram overlapping all RNA-binding proteins predicted to bind to PTBP2 3’UTR using three different RNA-binding protein prediction 
databases. Right, binding motifs on PTBP2 3’UTR of the two predicted candidate RNA-binding proteins (left) based on all predicted motifs on PTBP2 3’UTR 
from RBPmap.
(B) Top, first 500 bp of PTBP1 3’UTR with the first conserved miR-124 target site in red. Bottom, track views of nELAVL HITS-CLIP of the human brain at 
PTBP1 3’UTR (GSM129912, GSM129914).
(C) Top, first 500 bp of PTBP2 3’UTR with the first conserved miR-124 target site in red. Bottom, track views of nELAVL HITS-CLIP of the human brain at 





























Figure S6. Neuronal long genes are targets of miR-124 and nELAVLs 
(A) RT-qPCR for mature miR-124 expression and ELAVL3, showing reduced miR-124 and ELAVL3 expression upon KD treatment 
compared to CTL.
(B) Expression of genes associated with neuronal and neuronal progenitor identity in CTL and KD HNs.
(C) Peak inward sodium current amplitude of CTL and KD HNs. Data are represented in ± SEM from seven recorded cells from each 
condition. Two-tailed unpaired t-test (** P = 0.005).
(D) Resting membrane potential of CTL and KD HNs. Data are represented in ± SEM from seven recorded cells from each condition. 
Two-tailed unpaired t-test (ns P = 0.1191).




























































































































































































Figure S7. Identified neuronal transcripts that are bound by AGO and nELAVLs in HNs
(A) Top biological GO terms associated with the 77 genes that are predicted to be targeted by both AGO-miR-124 and 
ELAVL3, based on AGO HITS-CLIP in miNs, nELAVL HITS-CLIP in human brain, and HN RNA-seq with miR-124 and 
ELAVL3 knockdown.
(B) Track views of AGO HITS-CLIP in miNs and nELAVL HITS-CLIP in the human brain (GSM1299112, GSM1885137, 
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Gene name logFC adj.P.Val  Gene name logFC adj.P.Val 
ACAD10 2.69E-01 1.25E-03  MDM1 -2.89E-01 1.26E-04 
ACER2 -6.41E-01 2.75E-06  MFHAS1 -3.46E-01 4.90E-03 
ALAS1 4.42E-01 6.48E-08  MGAT4C -9.34E-01 1.15E-03 
ANGPTL1 2.62E-01 1.11E-04  MITF -3.52E-01 5.53E-03 
ANK3 -1.06E+00 4.61E-12  MRPL35 2.00E-01 2.01E-03 
APBA1 -3.58E-01 5.20E-03  MTHFR -4.84E-01 2.25E-07 
APOE 3.11E-01 2.59E-04  NEFM -7.36E-01 3.27E-06 
ARHGAP20 -2.58E-01 1.14E-03  NINJ1 3.22E-01 1.49E-05 
ARHGEF7 -2.45E-01 3.73E-04  NLGN2 2.99E-01 8.63E-03 
ATP6V0A1 -3.55E-01 4.02E-06  OGFRL1 -3.40E-01 7.90E-04 
ATP6V1G2 -7.71E-01 1.91E-11  OSBPL1A 4.04E-01 2.55E-06 
BCL7A -5.14E-01 2.80E-04  OXR1 -2.10E-01 5.70E-04 
BDH2 2.56E-01 1.23E-04  PASK -7.59E-01 2.82E-03 
BMF -9.39E-01 6.06E-10  PBX3 -9.96E-01 1.24E-09 
C14orf132 2.55E-01 8.72E-05  PCDH7 4.33E-01 8.56E-06 
CAMK4 -9.30E-01 6.86E-10  PCLO -1.42E+00 1.78E-04 
CAMSAP1 -4.72E-01 1.66E-04  PELP1 -4.45E-01 2.19E-03 
CDK15 -8.77E-01 3.34E-08  PER3 -5.22E-01 8.66E-06 
CDS1 -1.53E+00 4.75E-08  PFKM 4.86E-01 9.38E-10 
CDS2 -1.55E-01 6.90E-03  PGM2L1 3.27E-01 2.03E-05 
CEP85L -5.40E-01 4.77E-09  PHKA1 -4.32E-01 4.44E-04 
CERS6 -3.93E-01 1.22E-04  PHLPP1 -3.60E-01 1.38E-03 
CFI 1.73E-01 5.31E-03  PHYHIPL -7.93E-01 1.30E-03 
CHRDL1 -3.77E-01 4.16E-03  PLD6 -6.71E-01 1.74E-03 
CLCN4 -2.56E-01 1.76E-03  PNISR -2.62E-01 1.39E-05 
CLCN6 -6.20E-01 5.98E-10  PPA2 2.47E-01 1.13E-04 
CLDN11 4.59E-01 1.06E-07  PPM1D -3.89E-01 1.96E-04 
CLUL1 -1.53E+00 4.41E-16  PPM1H -9.24E-01 3.05E-11 
CNNM1 -8.45E-01 1.74E-05  PPP1R9A -1.14E+00 2.39E-11 
CNTN1 -1.15E+00 2.06E-05  PTBP2 2.45E-01 2.20E-04 
COX6C 4.76E-01 1.44E-08  PTN -8.37E-01 8.82E-11 
CPE 2.48E-01 1.51E-03  RALGAPA1 -2.61E-01 4.19E-03 
CRY1 -8.57E-01 1.47E-09  RALGPS1 -5.08E-01 1.06E-03 
CRY2 -6.05E-01 1.25E-07  RANBP3L -9.82E-01 8.23E-12 
CXADR -1.06E+00 1.24E-10  RAPGEF4 -1.70E+00 6.51E-09 
DCLK1 -8.70E-01 4.73E-13  RASL10B -6.35E-01 8.25E-04 
DHX30 -3.00E-01 8.47E-05  RCAN2 -7.31E-01 1.90E-12 
DKK2 -5.74E-01 1.69E-06  RIC3 -1.50E+00 6.66E-08 
DNAJB5 -6.00E-01 2.77E-09  RIMBP2 -1.19E+00 9.69E-05 
DOCK3 -4.80E-01 2.08E-04  RIMS2 -3.26E-01 2.58E-03 
DTNA -3.15E-01 4.16E-05  RNF157 -4.66E-01 6.72E-06 
DUSP26 -1.36E+00 3.71E-05  RNFT2 -8.03E-01 3.39E-11 
DUSP8 -1.98E+00 3.49E-07  RRAGD -1.64E+00 7.49E-15 
EEF1A2 -1.95E+00 4.25E-08  SAMD12 -1.21E+00 3.44E-09 
EFR3B -8.75E-01 6.22E-11  SCARB1 4.19E-01 6.87E-03 
ENOX1 -7.19E-01 1.34E-03  SCN1A -7.43E-01 8.57E-08 
EPB41 -3.94E-01 2.63E-03  SCN2A -2.24E-01 4.95E-03 
EPHA4 2.73E-01 9.07E-04  SCN9A -4.44E-01 4.53E-04 
FADS2 2.97E-01 2.50E-04  SDHA 4.27E-01 1.05E-08 
FAIM2 2.85E-01 8.55E-04  SEMA6A -1.15E+00 1.18E-09 
FAM110B -2.19E-01 1.48E-03  SENP7 -2.45E-01 3.82E-03 
FAM13C -3.07E-01 4.61E-06  SESN3 -3.27E-01 4.58E-04 
FAM184A -8.65E-01 3.96E-06  SFMBT2 -9.75E-01 2.02E-03 
FILIP1 -7.07E-01 3.53E-09  SFRP4 4.41E-01 4.72E-06 
FKBP5 -3.28E-01 2.16E-03  SH3BP2 3.52E-01 2.16E-04 
FRMD4A -4.16E-01 3.84E-05  SLC12A7 -6.84E-01 7.60E-04 
FSD1L -2.44E-01 9.50E-03  SLC25A11 2.73E-01 4.66E-05 
GABRE -2.10E-01 1.21E-03  SLC25A13 4.31E-01 1.64E-07 
GAD1 -9.23E-01 4.01E-07  SLC2A8 -8.54E-01 2.39E-03 
GDF11 -1.93E-01 9.47E-03  SLC4A8 3.30E-01 2.34E-04 
GDF5 -1.90E+00 1.49E-10  SLC7A14 -3.73E-01 3.33E-05 
GPM6A -8.05E-01 9.82E-03  SLITRK4 -6.47E-01 2.55E-03 
GPNMB 1.55E-01 7.24E-03  SMARCB1 -4.41E-01 1.38E-04 
GRIA2 -9.12E-01 1.05E-03  SNAP25 -5.52E-01 5.29E-10 











































Table S1. MiR-124-responsive genes that harbor AGO-enriched peaks in miNs 
List of upregulated genes during conversion harboring AGO-enriched peaks and are not upregulated 
upon miR-124 knockdown in miNs(TuD-miR-124 /TuD-miR-NS; Log2FC ≥ -0.5; adj. P.value > 0.01). 
HMGCS1 -5.84E-01 3.64E-11  SPP1 -8.26E-01 3.11E-07 
HTR2B -6.42E-01 6.61E-03  STAC2 4.69E-01 2.91E-03 
IGF1 2.00E-01 1.21E-03  STMN2 2.14E-01 3.39E-03 
IGSF10 -4.78E-01 1.99E-04  STRBP -6.99E-01 4.99E-07 
INPP1 3.61E-01 7.75E-06  STX1B -2.83E-01 6.24E-03 
IRF6 -2.34E+00 3.13E-14  SULT1C4 -5.37E-01 1.42E-05 
ITM2A -5.17E-01 2.47E-03  SV2A 1.74E-01 4.14E-03 
KALRN -2.41E-01 3.41E-03  SYBU -7.80E-01 3.87E-09 
KAT2B -3.56E-01 3.43E-03  TBC1D9 -3.30E-01 5.43E-03 
KCNK1 -6.44E-01 9.90E-03  THSD7A -6.27E-01 2.14E-03 
KIAA1109 -3.48E-01 3.91E-05  TKT 2.56E-01 4.20E-05 
KIAA1217 -4.34E-01 3.00E-06  TLE1 -4.92E-01 1.57E-05 
KIF5A -4.88E-01 3.85E-09  TM7SF3 2.20E-01 5.34E-03 
KIF5C -9.14E-01 1.40E-11  TMEM63B 4.40E-01 9.37E-04 
KLLN -4.85E-01 7.94E-04  TMEM8B -3.26E-01 5.29E-03 
KPNA5 -4.18E-01 8.78E-06  TMOD2 -4.14E-01 2.88E-06 
LCOR -3.31E-01 3.87E-05  TNFRSF14 -4.38E-01 4.31E-04 
LDB2 -2.28E-01 5.54E-03  TNFRSF21 4.14E-01 3.92E-06 
LDHB 4.57E-01 4.91E-09  TRAPPC9 -3.39E-01 6.05E-03 
LMBR1 3.07E-01 1.54E-03  TRPC3 -1.97E+00 1.84E-08 
LRRN3 -1.62E+00 1.43E-15  TSHZ1 -7.13E-01 5.06E-09 
MAGI2 -7.78E-01 1.74E-09  TSPAN14 2.02E-01 3.98E-03 
MAMDC2 3.69E-01 5.44E-04  TSPAN7 -1.55E+00 4.65E-04 
MAN1C1 -3.73E-01 2.77E-06  TXLNB -1.35E+00 3.82E-13 
MANSC1 -3.27E-01 2.30E-03  UPF3B 2.19E-01 8.66E-03 
MAP2 -2.94E-01 6.73E-05  UQCRC1 3.26E-01 1.40E-06 
MAP3K14 -3.27E-01 4.81E-03  WDR7 -3.75E-01 1.51E-05 
MAPRE3 -5.43E-01 3.36E-04  ZNF518A -3.87E-01 2.06E-04 
MBP -1.18E+00 5.45E-11  ZNF577 -3.15E-01 8.04E-04 
MCM3 -1.75E-01 9.94E-03  ZNF738 -2.97E-01 2.23E-03 





SEPT4 ANK1 ATP9A CALR CNTN1 DIP2B FAIM2 
AAK1 ANK2 ATPAF1 CAMK2D COA5 DIS3L2 FAM102A 
AASDHPPT 
ANKRD20A11
P ATXN1 CAMK2N1 COL1A2 DJA2 FAM122C 
AASS ANKRD36C ATXN10 CAMKK1 COL21A1 DJB6 FAM126B 
ABCA1 ANKRD44 AVL9 CAMSAP1 COL24A1 DJC5 FAM135A 
ABCA12 ANKRD46 AXIN2 CAMTA1 COL3A1 DJC6 FAM13B 
ABCA7 ANO8 B3GAT3 CAPZB COL4A5 DJC7 FAM13C 
ABCB4 ANP32A B3GLCT CBX5 COL5A2 DKK3 FAM169A 
ABCC6P1 ANXA11 B4GALT3 CCBE1 COLEC12 DLD FAM196B 
ABCC9 ANXA6 BAALC CCDC136 COLGALT2 DLEU2 FAM198B 
ABCD2 AP1B1 BAG6 CCDC149 COMMD2 DLG4 FAM20C 
ABCD3 AP1M1 BAZ2B CCDC64 COPG2 DLG5 FAM234B 
ABCG4 AP1S2 BBS9 CCDC7 COX6C DMPK FAM49B 
ABHD6 AP2S1 BCAS1 CCDC74A CPEB3 DMXL2 FAM65B 
ABLIM3 AP5M1 BCL7A CD109 CPEB4 DNM1 FAM66E 
ABR APBB1 BCL9 CD14 CPQ DNM3 FAM69B 
ABTB1 APC BDH2 CD36 CPSF6 DNPH1 FAM96A 
AC083843.4 APCDD1 BEND5 CD74 CREB1 DOCK10 FAP 
ACAD11 APLP2 BEND6 CDH18 CREM DOCK4 FAR2 
ACAD8 APOL4 BLID CDH6 CRLS1 DOK5 FAR2P2 
ACADM APOO BMP1 CDK14 CRMP1 DOT1L FASTKD1 
ACAN APP bP-21264C1.1 CDK15 CROT DPF1 FAT4 
ACAP3 AQP9 BRD3 CDK16 CS DPP3 FBLN2 
ACAT1 ARFGEF1 BRE CDK18 CSRNP3 DPT FBXL17 
ACBD5 ARG2 BRI3BP CDKL1 CTB-52I2.4 DPYSL2 FBXO9 
ACER2 ARHGAP12 BRMS1L CDS1 CTPS2 DPYSL4 FCMR 
ACER3 ARHGAP20 BRWD3 CEACAM1 CTSO DROSHA FER 
ACSF2 ARHGAP26 BTRC CEMIP CTSS DST FGD4 
ACSL4 ARHGAP32 C10orf10 CENPW CUL3 DT FGD6 
ACTR10 ARHGAP42 C11orf49 CEP85L CXADR DUSP23 FGF13 
ACTR3B ARHGEF10L C12orf75 CFI CXCL12 DUSP6 FH 
ACVR1B ARL5A C14orf37 
CH17-
472G23.4 CYB5R4 dydorbo FHOD3 
ACVR2A ARMC9 C15orf39 CHD4 CYFIP2 DYNC1I2 FIBIN 
ACVR2B ARRDC4 C15orf57 CHFR CYGB DYRK2 FILIP1 
ADAM17 ARSF C16orf45 CHI3L2 CYP3A4 EDIL3 FKBP2 
ADAM19 ARV1 C18orf54 CHR3 CYP3A5 EDNRA flawfybo 
ADAM22 ASAH1 C1orf220 CHRM2 CYP3A7 EEF2K FN3K 
ADAM23 ASAP1 C1QTNF1 CHST10 CYP46A1 EEPD1 FNDC1 
ADAMTS12 ASB9 C1QTNF6 CHST11 CYTH2 EFR3B FNDC4 
ADARB1 ATAD2B C2orf27A CIITA DAAM2 EHBP1 FNDC5 
ADCY1 ATAT1 C4A CISH DAB1 EIF5A2 FOXN3 
ADD2 ATF6B C4B CIT DAPK1 ELN FRAS1 
ADGRA3 ATF7IP C4orf27 CKB daseebo EMCN FRK 
ADGRL1 ATG4D C8orf34 CLASP2 DCBLD1 EML6 FRMD4A 
ADGRL2 ATP13A2 C9orf3 CLCN4 DCLK1 EMP2 FRMD5 
ADK ATP1A3 CABLES1 CLEC16A DCLK2 EN1 FAIM2 
AES ATP1B1 CABLES2 CLNS1A DCTPP1 ENPP5 FAM102A 
AF131217.1 ATP2B4 CABP2 CLSTN3 DCUN1D4 ENSA FAM122C 
AF186192.5 ATP5A1 CAC1A CLTA DDAH1 EPB41L1 FAM126B 
AGAP1 ATP5B CAC1G CLTC DDIT4L EPB41L3 FAM135A 
AGAP2 ATP5C1 CAC2D3 CLU DDR1 EPHA4 FAM13B 
AIFM1 ATP5G2 CACHD1 CLUH DDT EPHB2 FAM13C 
AIG1 ATP5L CACNB2 CLUL1 DDX39B EPHX2 FAM169A 
AK5 ATP6AP1 CACNB4 CLYBL DGCR8 EPS15 FAM196B 
ALAD2 ATP6V0A1 CACNG7 CNIH2 DHODH ETS1 FAM198B 
ALG9 ATP6V0E2 CADM1 CNIH3 DHX15 EVL FAM20C 
AMPD3 ATP6V1B2 CADM3 CNKSR2 DHX30 EXOC1 FAM234B 
AMPH ATP6V1C1 CALM1 CNOT8 DHX9 EXOC4 FAM49B 
ANGEL2 
ATP6V1G2-








FRMD5 HLF KIF26B MAP2 MYLK NEFM PCBP3 
FRMPD3 HMG20A KIF3B MAP2K6 MYO1B NEGR1 PCBP4 
FRY HMGB1 KIF3C MAP3K12 MYO5A NEK10 PCCA 
FYB HNRNPA3P3 KIF5C MAP3K13 MYOZ2 NELFCD PCCB 
GAB1 HOMER1 KLC1 MAP4K3 NBEA NET1 PCDHA9 
GABRA3 HOXA10 KLF3 MAPK10 NBEAP1 NETO2 PCDHB16 
GABRE HOXA13 KLHL13 MAPRE2 NCALD NEURL4 PCDHB18P 
GABRR1 HR KLRC4-KLRK1 MAPRE3 NCAM1 NFAT5 PCDHB8 
GAD1 HRAT17 KMT5B MAPT NCOA1 NFYC PCDHGC3 
GALC HSBP1 KP5 MATR3 NDN NID2 PCMTD1 
GALNT11 HSD17B4 LACC1 mawgar NDRG1 NIPSP3A PCSK5 
GALNT14 HSP90B1 LACTB MBOAT1 NDRG2 NKIRAS1 PCSK7 
GALNT5 HSPA12A LAMB1 MBTD1 NDRG4 NLGN4X PCYOX1L 
GAS1RR HSPB7 LARGE MCC NDUFAF5 NLK PDCL 
GAS7 HTT LBH MCM4 NDUFS1 NNT PDE1A 
GBP2 HUNK LCN MCOLN3 NDUFS2 NOL4L PDE3A 
GDF11 INA LEPR MCTP1 NDUFV2 NOMO3 PDE4B 
GGCT IAH1 LGALSL MDH1B NECAB3 NONO PDGFD 
GIPC1 IBTK LIMCH1 ME3 NEFL NPNT PDGFRA 
GLI3 IDH2 LINC00673 MEG3 NEFM NRCAM PDK1 
GLUL IGFBP2 LINC00702 MEGF8 NEGR1 NREP PDP1 
GNB5 IGFBP3 LINC00886 MEIS3 NEK10 NRG1 PDS5B 
GNG2 IGFL4 LINC01091 MEMO1 NELFCD NRP1 PDZRN3 
GP1BB IGK LINC01535 MEST NET1 NSF PELI2 
GPAA1 IGSF10 LINC01621 MET NETO2 NSFP1 PFKM 
GPCPD1 IKZF2 LLGL1 METTL9 NEURL4 NSG1 PFN2 
GPI IL17RB LMBR1 MFAP2 NFAT5 NSL1 PGD 
GPM6B IL17RD LMBR1L MGAT5 NFYC NSMF PGM2L1 
GPR155 IL6R LMO7 MGP NID2 NT5C2 PHACTR1 
GPR162 IL7 LOC100507002 MGST3 NIPSP3A NT5C3A PHACTR3 
GPR173 IMMT LOC101927686 MICAL2 NKIRAS1 NT5DC1 PHKA1 
GPR75-ASB3 INPP4B LOC101929710 MICU1 NLGN4X NTN4 PHYHIPL 
GPRC5B INPP5A LOC102723373 MICU3 NLK NTNG1 PI4KA 
GRAMD1B INSRR LOC102723769 MID1 NNT NTRK1 PI4KAP1 
GRAMD4 IQCJ LOC105378663 MINOS1P1 NOL4L NTRK3 PI4KAP2 
GREM1 ITGA11 LOC220729 MIR22HG NOMO3 NUAK1 PIAS4 
GS ITGA2 LOC645513 MIR29A NONO NUDCD3 PIK3CB 
GSR ITGA5 LOC728730 MIR4500HG NPNT NUDT22 PIK3R1 
GSTM2 ITGAV LPAR6 MIR573 NRCAM NUDT3 PIK3R2 
GTF2I ITM2A LPCAT1 MIR99AHG NREP OBSCN PIK3R3 
GTF2IP1 ITSN1 LPP-AS2 MLIP MYLK OGDH PIN1 
GTF3C1 JARID2 LRP4 MLLT11 MYO1B OGFRL1 PIP4K2A 
GTF3C2 JPH2 LRP5 MMD MYO5A OIP5-AS1 PIP5K1C 
GUCY1B3 KALRN LRRC32 MMP16 MYOZ2 ORMDL3 PITPNM1 
GULP1 KCB2 LRRC40 MOB4 NBEA OSBP2 PKIA 
GXYLT2 KCNC4 LRRC49 moymoyby NBEAP1 OSBPL1A PKIG 
H2AFY KCNH5 LRRK2 MPC1 NCALD OSCP1 PKM 
H2AFY2 KCNK2 LSAMP MREG NCAM1 OSR1 PLA2G15 
H3F3B KCNMA1 LUCAT1 MROH7 NCOA1 OXTR PLA2G4A 
HABP4 KDM4C LYNX1 MRPL35 NDN P1L5 PLAGL1 
HAGH KDM5B LYST MRPS7 NDRG1 P4HTM PLCB1 
HDAC5 KHDRBS1 maby MSI1 NDRG2 PAFAH1B2 PLCB4 
HDAC9 KIAA0391 MAFB MT1F NDRG4 PAK1 PLCD4 
HECW1 KIAA0895L MAGI1 MTMR1 NDUFAF5 PANK1 PLCH1 
HEPH KIAA0922 MAGI3 MTMR9 NDUFS1 PARM1 PLD1 
HIST4H4 KIAA1109 MAMDC2 MTSS1L NDUFS2 PARP8 PLEKHA2 
HK1 KIAA1644 MAN1C1 MTUS1 NDUFV2 PB PLEKHA5 
HK2 KIF1B MAOA MXRA5 NECAB3 PBX1 PLIN2 
HLA-DRA KIF21A MAP1B MYH10 NEFL PBX3 PLK2 
PLPPR4 RALGAPA1 SCP2 SLC9B2 SVILP1 TP53I11 WARS2-IT1 
PLS3 RALGAPA2 SCRG1 SLIT2 SYNE1 TP53I3 WASF3 







PLXDC1 RALGPS1 SDHA SMARCA2 SYNJ1 TPCN1 WDR37 
PLXDC2 RANBP3L SDHAP3 SMARCA4 SYNJ2 TPD52L1 WDR41 
PLXNC1 RAP1GAP2 SDK2 SMARCC2 SYNPO2 TRAK1 WDR63 
PLXND1 RASA3 SEC14L1 SMG6 SYPL2 TRAPPC2 WDR7 
PMAIP1 RASGRP3 SEC61A2 SMIM10L2A SYT1 TRDMT1 weewerby 
POLR2E RASL10B SECTM1 SNN T14 TRERF1 WHSC1 
POLR3A RBM12B SEMA3D SNRPA TADA2A TRIB1 WWP2 
POLR3F RBM24 SEMA6B SNRPA1 TANC1 TRIM16L XPNPEP1 
POMGNT1 RBMX SEMA6D SOCS2 TAPT1 TRIM2 YAF2 
POMK RERE SENP7 SOCS2-AS1 TBC1D12 TRIM24 yara 
POR REREP3 SEPN1 SOGA3 TBC1D8 TRMT2B YLPM1 
POSTN REV3L SEPT7P2 SORBS1 TBCB TRPC3 YPEL3 
PPARD RFTN1 SEPW1 SORL1 TBCK TSPAN13 YWHAE 
PPARGC1A RGL1 SERPINF1 SOX4 TCIRG1 TSPAN15 ZC2HC1A 
PPFIA4 RGS16 SERPINI1 SPAG17 TCN2 TSPAN18 ZC3H12B 
PPIA RGS3 SETBP1 SPARC 
TCONS_l2_000
02184 TSPAN3 ZCCHC2 
PPIAL4C RGS4 SFRP4 SPARCL1 
TCONS_l2_000
26703 TSPAN5 ZDHHC13 
PPP1R12B RGS8 SGIP1 SPATA13 
TCONS_l2_000
30954 TSPAN7 ZDHHC15 
PPP1R14B RHOBTB1 SH3BP2 SPATA20 TDO2 TSSC1 ZDHHC16 
PPP1R21 RIMS2 SH3BP5 SPATA6 TENM4 TTC13 ZDHHC9 
PPP2R1B RIT1 SH3GLB2 SPC3 TFAM TTC19 ZEB1-AS1 
PPP2R2B RMDN2 SHOX2 SPIDR TGFBI TTC33 ZFAND5 
PPP2R2D RNF150 SHTN1 SPOCK1 TGM2 TTLL6 ZFAND6 
PPP2R3A RNF38 SIAE SPRY1 THRA TTYH3 ZFHX4 
PPP5C RNFT2 SIPA1L3 SPRYD3 THRB TUBA4A ZFP14 
PQLC2L ROR1 SIRPA SPSB1 THSD7A TUBB3 ZFP30 
PREP RP11-353N14.1 SIRT2 SPTLC3 TIAF1 TUBG2 ZMIZ1 
PREX1 RP11-359M6.1 SIX1 SRD5A1 TIMM8B TXNRD2 ZMYND8 
PREX2 RP11-368L12.1 SLAIN1 SRGAP2 TIPARP UACA ZNF124 
PRH1 RP11-395N3.2 SLC16A3 SRSF1 TKT UBA5 ZNF195 
PRICKLE1 RP11-402L1.11 SLC16A4 SRSF3 TLE3 UBE2N ZNF24 
PRIM2 RP11-417J8.3 SLC16A7 SSBP3 TLN2 UBP1 ZNF254 
PRKAA2 RP11-435B5.5 SLC1A2 ST3GAL3 TLR1 UBR7 ZNF33A 
PRKCA RP11-442J21.2 SLC22A17 ST3GAL5 TLR4 UNC13B ZNF347 
PRKCQ-AS1 RP11-575F12.3 SLC22A23 ST3GAL6 TMCC1 UPRT ZNF385D 
PRKG1 RP11-61O11.1 SLC22A3 ST6GALC6 TMEM108 UQCRB ZNF430 
PRKG2 RP11-782C8.2 SLC25A12 ST8SIA4 TMEM120A UQCRC1 ZNF436 
PRLR RP11-88I18.2 SLC25A13 STAC2 TMEM132A UQCRH ZNF444 
PROS2P RP4-665J23.1 SLC25A23 STAU2 TMEM136 UROS ZNF454 
PRSS12 RP5-1172A22.1 SLC25A27 STK32B TMEM161B USP11 ZNF493 
PRTFDC1 RPS6KA3 SLC25A29 STK33 TMEM173 USP33 ZNF506 
PRUNE2 RPS6KA6 SLC25A5 STMN1 TMEM178A USP46 ZNF540 
PSD3 RPUSD3 SLC2A5 STMN2 TMEM2 UTRN ZNF608 
PSMB8-AS1 RRAGD SLC35B4 STON2 TMEM25 V1 ZNF609 
PTBP2 RSRC1 SLC38A1 STX12 TMEM50B V3 ZNF618 
PTGDS RUFY3 SLC38A2 STX1B TMEM59L VAMP4 ZNF676 
PTGFR RUNX1T1 SLC38A7 STX7 TMEM63B VAV3 ZNF680 
PTPN13 S1PR1 SLC39A10 STXBP1 TMEM8A VCAM1 ZNF708 
PURG SACS SLC4A2 STXBP5 TMOD2 VDAC1 ZNF709 
PXYLP1 SAMD14 SLC4A4 SUB1 TMOD3 VEZT ZNF718 
PYGB SARDH SLC4A7 SUCLA2 TMTC2 VNN1 ZNF75D 
RAB13 SBF2 SLC6A17 SULF2 TMTC4 VOPP1 ZNF85 
RAB26 SCG5 SLC6A8 SUMO2P18 TNFRSF19 VPS13C ZNRF2 
RAB3A SCML1 SLC7A6 SUN1 TNIK VPS36 ZYG11B 
RAB3C SCN1A SLC8A1 SUSD4 TNRC6B VSNL1  
rahiyu SCN1B SLC9A9 SVIL TNS3 vubler  
 
 
Table S2. Neuronal genes with PTBP2-mediated splicing events 
List of neuronal genes (upregulated in miNs / HAFs; FC ≥ 1.5; ANOVA P < 0.05) exhibiting splicing 




Gene name logFC Adj.P.Val  Gene name logFC Adj.P.Val  Gene name logFC Adj.P.Val 
ABCD2 -1.83E+00 9.79E-03  KCTD12 -2.29E+00 1.44E-04  THSD7A -1.32E+00 3.91E-03 
ADAM22 -1.65E+00 9.21E-04  KIAA0513 -1.34E+00 1.41E-03  TMEM108 -1.26E+00 6.35E-03 
ADAM23 -1.25E+00 1.76E-02  KIF5C -1.34E+00 4.06E-03  TMOD2 -1.76E+00 1.57E-03 
ADCY1 -2.44E+00 5.06E-05  KLHL25 -1.32E+00 1.78E-03  TMTC2 -1.29E+00 1.11E-03 
AMOT -1.20E+00 2.04E-02  LRRC4 -1.37E+00 4.46E-03  TNFRSF21 -1.07E+00 2.03E-02 
ANK3 -1.07E+00 7.83E-03  MAGI3 -1.48E+00 3.88E-04  TSPAN14 -1.11E+00 5.54E-03 
ANKRD6 -2.24E+00 1.15E-05  MAP2 -1.79E+00 5.20E-04  TSPAN5 -1.34E+00 1.07E-03 
APBA1 -1.71E+00 3.05E-04  MCM3 -1.40E+00 3.98E-04  TSPAN7 -2.67E+00 8.68E-06 
APBB1 -1.35E+00 1.87E-03  METTL7A -1.80E+00 5.74E-05  TUB -1.31E+00 8.61E-04 
APOE -1.87E+00 3.09E-04  MGAT4C -2.81E+00 5.42E-03  TUBB3 -2.41E+00 1.08E-04 
ARHGEF7 -1.03E+00 3.36E-03  NCALD -2.21E+00 3.83E-05  ZNF300 -1.49E+00 6.27E-03 
ASTN1 -1.64E+00 3.52E-04  NCAM1 -1.66E+00 8.27E-04  ZNF536 -1.16E+00 1.39E-02 
ATP6V1G2 -1.33E+00 2.66E-02  NELL2 -2.45E+00 2.15E-05     
BAALC -2.20E+00 3.83E-05  NFIB -1.33E+00 3.05E-03     
BCL7A -1.24E+00 1.66E-03  OGFRL1 -2.46E+00 2.85E-05     
C14orf132 -2.08E+00 4.63E-05  P2RY1 -2.81E+00 1.78E-03     
CALB2 -3.41E+00 7.54E-05  PASK -1.53E+00 4.18E-02     
CAMK4 -1.05E+00 2.17E-02  PEG10 -3.04E+00 2.97E-06     
CAMSAP1 -1.28E+00 2.73E-03  PHYHIPL -2.49E+00 9.40E-05     
CDC7 -1.98E+00 1.97E-03  PLCXD2 -2.58E+00 1.68E-04     
CERS6 -2.50E+00 6.64E-05  PODXL2 -1.18E+00 7.68E-03     
CHRDL1 -2.53E+00 1.88E-05  PPM1L -1.60E+00 2.84E-04     
CKB -1.40E+00 2.44E-03  PPP1R12B -1.76E+00 5.18E-05     
CLCN4 -1.32E+00 5.14E-03  PRRT2 -2.31E+00 7.95E-05     
CNTFR -1.23E+00 2.41E-02  PTBP2 -1.70E+00 3.41E-02     
CNTN1 -1.81E+00 9.97E-03  PTCHD1 -1.34E+00 4.35E-02     
CPE -1.29E+00 2.47E-03  RAB3A -2.17E+00 1.87E-04     
CRISPLD1 -2.00E+00 3.63E-04  RALGPS1 -2.01E+00 2.87E-05     
CRMP1 -2.33E+00 1.23E-04  RIMS3 -1.61E+00 3.27E-04     
CRY1 -1.30E+00 1.28E-03  RIMS4 -1.85E+00 5.99E-04     
CSRNP3 -1.57E+00 1.22E-02  RNF144A -1.18E+00 3.01E-03     
CXADR -1.62E+00 2.73E-02  RNF157 -1.38E+00 1.33E-03     
CYFIP2 -1.14E+00 6.06E-03  RNFT2 -1.37E+00 4.52E-04     
DCLK1 -2.28E+00 4.58E-05  RRAGD -1.05E+00 2.73E-02     
DCLK2 -2.34E+00 7.21E-06  RUFY3 -1.98E+00 1.46E-03     
DPF1 -2.38E+00 8.68E-05  SBK1 -1.75E+00 3.09E-03     
EFR3B -1.24E+00 5.25E-03  SCD5 -1.08E+00 3.36E-03     
ENOX1 -1.85E+00 5.62E-03  SCN1A -3.60E+00 1.65E-05     
FADS2 -1.73E+00 4.46E-04  SEMA6A -1.29E+00 1.66E-03     
FAM110B -1.36E+00 7.31E-04  SERTAD4 -2.34E+00 1.04E-02     
FAM131B -1.31E+00 1.75E-03  SESN3 -3.07E+00 1.32E-03     
FAT3 -1.51E+00 9.85E-04  SFRP4 -3.54E+00 1.99E-02     
FGD4 -1.51E+00 8.35E-03  SH3BP2 -1.28E+00 1.50E-03     
FOXP2 -2.99E+00 3.85E-02  SHF -2.00E+00 4.03E-04     
FRY -1.86E+00 5.51E-05  SIAH3 -2.40E+00 4.45E-04     
FZD3 -1.45E+00 2.68E-02  SLAIN1 -2.35E+00 4.30E-05     
GAD1 -1.28E+00 7.76E-04  SLC1A2 -2.34E+00 1.89E-04     
GDAP1 -1.34E+00 7.20E-03  SLC4A8 -1.07E+00 3.90E-03     
GPC2 -1.86E+00 1.37E-04  SMAP1 -1.01E+00 1.27E-02     
GPD1L -2.63E+00 4.06E-04  SNAP25 -1.29E+00 2.67E-03     
GPM6A -2.35E+00 3.96E-04  SNCAIP -3.29E+00 9.75E-07     
GPR173 -1.19E+00 1.81E-02  SPARCL1 -1.35E+00 1.21E-02     
GRIA2 -1.74E+00 2.32E-03  SPTBN2 -1.14E+00 6.80E-03     
GRIA4 -1.33E+00 6.84E-03  SRGAP3 -1.01E+00 1.13E-02     
GRM5 -2.06E+00 3.30E-02  STMN2 -3.04E+00 1.01E-05     
GUCY1A2 -1.54E+00 1.75E-02  STMN3 -2.03E+00 1.84E-04     
HMGCS1 -2.22E+00 6.55E-03  STRBP -1.40E+00 3.94E-03     
IL17RD -2.54E+00 9.18E-06  SYBU -2.25E+00 5.04E-05     
JPH4 -1.31E+00 6.71E-03  SYT1 -1.25E+00 8.81E-03     
KALRN -1.45E+00 4.23E-04  THRA -1.09E+00 8.51E-03     
 
Table S3. MiR-124-responsive genes that harbor AGO-enriched peaks in HNs 
List of downregulated DEGs (KD / CTL; Log2FC ≥ 1; adj. P.value > 0.05) in HNs with miR-124 and 























































Table S4. MiR-124-responsive genes predicted to be bound by nELAVLs in HNs 














Chapter 4: PTBP2-mediated alternative 





PTBP2 targets chromatin modifiers to facilitate histone mark 
recognition 
A significant subset of the identified PTBP2 targets during neuronal reprogramming was 
chromatin regulators (Chapter 3), suggesting the role of PTBP2 in regulating epigenetic effectors 
during neuronal fate acquisition. One of the identified targets in the array was DPF1 (Chapter 3). 
DPF1 (also known as BAF45B) is a subunit of the BAF chromatin remodeling complex that is 
specifically expressed in neurons and define the neuron specific-assembly of BAF complexes 
along with BAF45C and BAF53B (Lee et al., 2018; Lessard et al., 2007; Wu et al., 2007) (Figure 
1A). We found that PTBP2 mediates the exclusion of a 30 base pair sequence in DPF1 
transcript, which is confirmed by RT-PCR using primers that flank the target spliced exon to 
generate amplicons corresponding to 216 bp (DPF1-Long/DPF1-L) and 186 bp (DPF1-
Short/DPF1-S) in length (Figure 1B-C). In our reprogrammed neurons or miNs, the shorter 
isoform DPF1-S transcript is the primary isoform, which shifts to include more of the DPF1-L 
isoform after PTBP2 knockdown (Figure 1B). While both DPF1-L and DPF1-S isoforms are 
detected in the human brain (Figure 1D), spike-in sequencing of DPF1 transcripts from human 
primary neurons indicated that majority of the DPF1 population 79.4%, maps to DPF1-S while 
20.6% maps to DPF1-L (Figure 7E). This miN-enriched DPF1-S appears to be a neuronal-
enriched isoform as in the human cerebral cortex (Figure 1D) (Uhlen et al., 2015).  
 The 30 bp difference between DPF1-S and DPF1-L falls within the second functional 
plant homeodomain (PHD) (Figure 1F). We examined the functional implications of having 
different PHD lengths. First, we found that both isoforms could still interact with BRG1, the core 
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Figure 1. Spliced DPF1 isoforms in human neurons differed in PHD domain length
(A) Schematic representing the switching of homologous subunits within the chromatin remodeling BAF (BRG1/BRM-associated 
factor) complex during neurogenesis. ACTL6A, SS18,
and PHF10 of the neural progenitor BAF complex switches to ACTL6B, SS18L1, and DPF1/DPF3, respectively, for the neuron-specif-
ic BAF complex.
(B) Left, schematic of primers used to confirm DPF1 splicing event from the array to generate amplicons of 216 bp and 186 bp 
corresponding to DPF1-L and DPF1-S, respectively. Right, RT- PCR of DPF1 splicing events in different backgrounds.
(C) Chromatograms showing Sanger sequencing results from 2 clones with (DPF1-L) or without (DPF1-S) the 30 bp spliced 
sequence from human brain cDNA library.
(D) Track view of DPF1 from the human cerebral cortex (ERX288614) (adapted from Uhlen et al., 2015) showing two DPF1 isoforms 
with the shorter isoform (DPF1-S) being more dominant in the brain.
(E) Spike-in sequencing of primary human neuron cDNA to determine the percentage of DPF1- S (79.4%) and DPF1-L (20.6%) 
isoforms from total reads.
(F) Diagram of DPF1 splicing pattern with alternative 3’ splice site for exon 11 generating two spliced DFP1 mRNAs, DPF1-S and 
DPF1-L, corresponding to differences in PHD2 domain length.
(G) Co-IP analysis revealed that both DPF1 isoforms could interact and incorporate into BRG1/BAF complex.
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interact preferentially to different histone H3 marks as previous studies indicated the ability of 
proteins with PHD fingers to interact with histone H3 modifications (Huber et al., 2017; Lange et 
al., 2008; Sanchez and Zhou, 2011). Using histone H3 peptide array ELISA, we compared the 
ratio of binding intensity between DPF1-S and DPF1-L. We found that DPF1-S was able to bind 
nine H3 modifications much more robustly than DPF1-L (³ 2 fold difference), including 
H3K9ac, H3K79me2, and H3K9me1 (Figure 1H). These results suggest that DPF1-S may likely 
be involved in the enhancement of BAF complex activity to recognize specific histone marks.  
PTBP2 is crucial for neuronal conversion 
Reducing PTBP2 expression led to the increased appearance of DPF1-L (Figure 1B) 
confirming that PTB switching in neurons is critical to confer the alternative splicing of DPF1 to 
DPF1-S isoform. Our results thus demonstrate the significance of PTBP2 function in executing 
the proper processing of neuronal genes activated in response to miR-9/9*-124 while the loss of 
PTBP2 would block neuronal conversion (Chapter 3; Figure 2A). Contrastingly, sequential 
knockdown of PTBP1 and PTBP2 proteins have been shown to be able to reprogram human 
fibroblasts into neurons (Xue et al., 2016). However, comparing the conversion efficiency by 
miR-9/9*-124 and PTBP1/2 sequential knockdowns points to the limited efficacy with PTB 
knockdowns only (Figure 2B-C). This difference is likely due to the presence of neurogenic 
factors such as nELAVLs (Chapter 3) and/or other neuronal RBPs evoked by miR-9/9*-124 
ensuring robust PTBP2 expression and activation of the neuronal program (Chapter 3), including 
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Figure 2. PTBP2 is crucial for neuronal conversion
(A) Top, schematic of miRNA-mediated reprogramming paradigm in which both miR-9/9*-124 and shRNA against PTBP2 were transduced 
WRJHWKHUDW3,'%RWWRP3,'PL1VZLWK&7/RU37%3NQRFNGRZQLPPXQRVWDLQHGZLWK37%3DQG78%%6FDOHEDU ȝP
(B) Top, schematic of sequential reprogramming. The first shRNA was transduced at PID 0 followed by a second shRNA transduced at PID 4 or 4 
days after the first shRNA transduction. Bottom, PID 30 cells after sequential knockdown using shRNAs against CTL, PTBP1, and/or PTBP2 
LPPXQRVWDLQHGZLWK37%3DQG78%%6FDOHEDU ȝP
(C) Quantification of TUBB3-positive cells over DAPI-positive cells with two or more processes in (A) and (B). Data represented as mean ± SEM. 
i) shCTL ii) shCTL n = TUBB3 2/293; i) shPTBP1 ii) shCTL n = TUBB3 1/67; i) shPTBP1 ii) shPTBP2 n = TUBB3 2/54; miR-9/9*-124 shCTL n = 













 In this thesis, we uncovered the role of miR-124 in the upregulation of genes associated 
with neuronal differentiation and function during the neuronal conversion of human fibroblasts. 
This finding provides insights into the function of miRNAs in addition to their canonical role as 
a repressor of downstream target genes. Of the bound AGO transcripts are bona fida miR-124 
target genes in which the 3’UTRs can be repressed in a non-neuronal context, but reverses upon 
neuronal induction. By examining the mutually exclusive regulation of PTBP1 and PTBP2, we 
reveal how miR-124 plays a bifunctional role depending on the sequence composition at the 
3’UTR, the availability of neuronal ELAVLs, and the interaction with AGOs to mediate the 
switching of PTB homolog expression during the neuronal conversion of HAFs. Although we 
focus specifically on the interplay between miR-124 and ELAVL3 for PTBP2 upregulation, 
future studies should also examine if similar mechanism is used to promote other identified 
neuronal transcripts or if other RBPs can also synergize with AGOs for such target gene 
regulation. For example, FXR1, an RBP, has been shown in previous studies to interact with 
AGOs to facilitate gene expression in non-neuronal cells (Truesdell et al., 2012; Vasudevan et 
al., 2007; Vasudevan and Steitz, 2007).  
The selective role of ELAVL3, and not ubiquitous ELAVL1 or neuronal-specific 
ELAVL2 and ELAVL4, in mediating PTBP2 induction in neurons highlights the functional 
specificity of ELAVL family members in neurons. Like ELAVL3, ELAVL1 binds AREs and has 
been shown to interact with RISC components (Kim et al., 2009; Vasudevan and Steitz, 2007). 
Although different studies reveal opposing consequence of RISC and ELAVL family interaction 
on target genes, downstream functional output of AGO-ELAVL is likely context dependent. This 
context depends on not only the concurrent availability of RBP and target transcript, but also the 
3’UTR sequence. Our results clearly define the functional specificity inherent in ELAVL3 that 
75 
 
cannot be replaced by ELAVL1, especially for regulating PTBP2 expression with miR-124 in 
neurons. We found that the specificity is, at least in part, driven by the hinge region inferred by 
the region-swapping experiments between ELAVL1 and ELAVL3. As there is no known ARE 
recognition unique to each ELAVL family member, it is likely that interactors associating with 
the hinge region may be regulating ELAVL specificity and targeting (Fujiwara et al., 2012; 
Hinman et al., 2013).  
To investigate if the synergism of miR-124 and nELAVLs for transcript stabilization and 
activation can be generalized to other neuronal transcripts beyond PTBP2 outside the conversion 
system, we also knockdown miR-124 and ELAVL3 in primary human neurons. Our results 
indicate that several neuronal transcripts are induced by miR-124 and ELAVL3 that are critical 
for neuronal program. Furthermore, by examining existing nELAVL HITS-CLIP datasets in the 
human brain (Scheckel et al., 2016), we uncovered that miR-124- and nELAVL-mediated 
upregulation of target transcripts may not be a unique occurrence to PTBP2, but likely an 
overlooked mechanism that maintains gene expression in neurons. Interestingly, as we identified 
numerous neuronal genes to be targets of miR-124, such as MAP2, CAMK1D, and SEMA6A, we 
argue that miR-124 may be critical for enhancing the overall neuronal program as measured by 
the reduced sodium current, and neurite length and branches through its regulation on long 
genes. By chemically inhibiting LGE in rat neurons, mimicking the transcriptomic phenotype 
observed in HNs with reduce miR-124 and ELAVL3 activity, we observed a variety of altered 
electrical properties. This finding also indicates that miR-9/9*-124 is highly neurogenic as these 
miRNAs not only allow for the conversion of HAFs into neurons (Abernathy et al. 2017; Yoo et 
al. 2011), but also enhanced the expression of neuronal markers, such as MAP2, when 
overexpressed during neuronal differentiation of human pluripotent stem cell-derived neurons 
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(Ishikawa et al., 2020; Sun et al., 2016). Although further tests are required to see if all the 
identified transcripts targeted by both miR-124 and nELAVLs share the same mechanism as 
PTBP2, our loss-of-function results from in both reprogramming and primary human neuron 
systems, and its effect on other neuronal genes lend support to the general role of miR-124 as a 
positive regulator of select target genes in neurons. Future experiments taking a closer look at 
RNA structure, motif proximity with RBPs, and additional interacting proteins will provide 
further mechanistic insights to how a single miRNA can simultaneously repress and activate 
different transcripts in a cell context-dependent manner.  
Our study offers insights into the bifunctional mode of miR-124 conferring miRNAs as a 
reprogramming effector that can contribute to the neuronal program by upregulating specific 
neuronal genes. As miRNAs have been typically checked for their targets in non-neuronal cell 
lines, it is plausible that the dual-mode of miRNAs may not be unique to miR-124 in neurons, 
but instead utilized and altered in other cellular contexts with the help of cell type-specific RBPs. 
The governance of miRNA activity by the sequences within 3’UTR highlights the role of cell 
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